1 ATRIP deficiency impairs the replication stress response and manifests as 2 microcephalic primordial dwarfism and immunodeficiency.

- 3 Authors: Evi Duthoo^{1,2,3}†, Elien Beyls^{1,2,3}†, Lynn Backers^{1,4,5}†, Thorkell Gudjónsson⁶, Peiquan Huang⁶,
- 4 Leander Jonckheere^{7,8}, Sebastian Riemann^{8,9}, Bram Parton^{4,5}, Likun Du¹⁰, Veronique Debacker^{1,2},
- 5 Marieke De Bruyne^{4,5}, Levi Hoste^{1,11}, Ans Baeyens¹², Anne Vral¹², Eva Van Braeckel^{7,8}, Jens Staal^{13,14},
- 6 Geert Mortier¹⁵, Tessa Kerre^{2,16}, Qiang Pan-Hammarström¹⁰, Claus Storgaard Sørensen⁶, Filomeen
- 7 Haerynck^{1,2,17}^{‡*}, Kathleen BM Claes^{4,5}^{‡*}, Simon J Tavernier^{1,2,4,13,14}[‡]
- 8 [†] These authors contributed equally to this work, [‡] These authors share last authorship, ^{*} Corresponding authors
- ¹Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent,
 Belgium.
- ²Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent,
 Belgium.
- ³Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
- 14 ⁴Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
- ⁵Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
- ⁶Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen,
 Denmark.
- ⁷Respiratory Infection and Defense Lab (RIDL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent,
 Belgium.
- 20 ⁸Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
- ⁹Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Internal Medicine and Pediatrics,
 Ghent University, Ghent, Belgium.
- ²³ ¹⁰Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- 24 ¹¹Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.
- ²⁵ ¹²Radiobiology Lab, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
- ²⁶ ¹³Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
- ²⁷ ¹⁴Unit of Molecular Signal Transduction in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium.
- 28 ¹⁵Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
- ¹⁶Department of Hematology, Ghent University Hospital, Ghent, Belgium.
- 30 ¹⁷Department of Pediatric Respiratory and Infectious Medicine, Ghent University Hospital, Ghent, Belgium.
- 31
- 32 Correspondence:
- 33 Email: Filomeen.Haerynck@ugent.be, Kathleen.Claes@ugent.be

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ABSTRACT

ATR (Ataxia Telangiectasia and Rad3-related) kinase and its interacting protein ATRIP orchestrate the 35 replication stress response. Two patients of independent ancestry with microcephaly, primordial 36 37 dwarfism, and recurring infections were found to be homozygous for splice donor site variants of ATRIP 38 exon 5, resulting in ATRIP deficiency. The c.829+5G>T patient exhibited autoimmune hemolytic 39 anemia, lymphopenia, poor vaccine response, and intermittent neutropenia. Immunophenotyping 40 revealed reduced CD16⁺ NK cells and absent naïve T cells, mucosal-associated invariant T cells 41 (MAITs), and invariant natural killer T cells (iNKTs). Lymphocytic defects were characterized by T cell 42 receptor (TCR) oligoclonality, abnormal class switch recombination (CSR), and impaired T cell 43 proliferation. ATRIP deficiency resulted in low-grade ATR activation but impaired CHK1 44 phosphorylation upon genotoxic stress. Consequently, ATRIP deficient cells inadequately regulated 45 DNA replication, leading to chromosomal instability, compromised cell cycle control, and impaired cell viability. CRISPR-Select^{TIME} confirmed reduced cell fitness induced by both variants. This study 46 establishes ATRIP deficiency as a monogenic cause of microcephalic primordial dwarfism, highlights 47 48 ATRIP's critical role in protecting immune cells from replication stress, and brings a renewed 49 perspective to the canonical functions of ATRIP.

50 INTRODUCTION

51 Maintaining genomic integrity requires cells to deploy defense mechanisms to counteract various DNAdamaging assaults. The phosphatidylinositol 3-kinase-related kinases (PIKKs) ATR, ATM, and DNA-52 53 PKcs act as key mediators of the DNA damage response (DDR), initiating signaling cascades that coordinate cell cycle progression, checkpoint activation, and concurrent DNA repair^{1,2}. While ATM and 54 55 DNA-PKcs respond to DNA double-strand breaks (DSBs), ATR primarily safeguards DNA synthesis during the S phase^{2,3}. RPA-coated single-stranded DNA (ssDNA) arises after processing of damaged 56 57 DNA, including stalled replication forks, resected DSBs, and UV-induced bulky adducts, and serves as 58 a platform for ATR activation. By phosphorylating substrates such as CHK1, ATR orchestrates the 59 replication stress response, triggering intra-S and G2/M checkpoints, suppressing origin firing, stabilizing replication forks, and promoting replication fork restart^{4–6}. ATR is essential for mammalian 60 DNA replication and complete loss of ATR was shown to result in early embryonic lethality in mice⁷⁻ 61 ¹¹. A homozygous hypomorphic leaky splice variant in ATR (NM 001184.4 (ATR): c.2022A>G, 62 p.(Gly674=)) was first reported by O'Driscoll et al.¹² in two families with Seckel Syndrome¹³ (OMIM 63 64 210600), a form of microcephalic primordial dwarfism (MPD) associated with intellectual disability and 65 distinct craniofacial features. To date, four additional ATR patients have been described, all harboring biallelic hypomorphic variants, leading to highly diminished but not abolished ATR protein levels^{14–16}. 66

67

68 The ubiquitously expressed ATR-interacting protein (ATRIP) is an essential binding partner of ATR, illustrated by the co-dependency of ATRIP and ATR for protein stability¹¹. On a functional level, ATRIP 69 70 recognizes and binds RPA-ssDNA nucleoprotein filaments, allowing ATR recruitment and subsequent activation by the kinases TOPBP1 and the recently identified ETAA1¹⁷. The structural basis for this 71 72 signaling nexus has recently been resolved: the N-terminal RPA-binding motif of ATRIP directly 73 interacts with RPA while its coiled-coil domain is required for the simultaneous homodimerization of 74 two ATRIP molecules. Through its C-terminal HEAT motifs, ATRIP associates with the N-terminal region of ATR and these ATR-ATRIP complexes form stable dimers of heterodimers upon recruitment 75 to RPA-ssDNA¹⁸⁻²⁰. Mutational analyses revealed that ATRIP-TOPBP1 interactions and downstream 76 77 ATR activation depend on a region adjacent to the coiled-coil domain in ATRIP²⁰. Unlike TOPBP1, 78 which relies on both ATRIP and the RAD9-RAD1-HUS1 (9-1-1) clamp for recruitment to the ATRIP-79 ATR complex, ETAA1 directly interacts with RPA-ssDNA and ATR^{17,21,22}. Defective ATRIP function 80 is associated with human disease as reduced ATRIP expression was found in a patient with MPD¹⁴ and heterozygous ATRIP loss-of-function variants have been associated with breast cancer susceptibility²³. 81 82 Moreover, conditional ATRIP loss in the central nervous system in mice resulted in microcephaly,

83 providing further evidence for a causal link between ATRIP deficiency and MPD^{24} .

84

85 MPDs are a genetically heterogenous group of overlapping disorders, defined by severe microcephaly and intrauterine and postnatal growth restriction. Pathogenic variants associated with MPDs have been 86 87 identified in genes involved in seemingly distinct cellular processes such as DNA replication initiation, DNA repair, cell cycle progression, and centrosome function^{25–28}. Disruption of the encoded proteins 88 89 consistently restrict cell proliferation dynamics, thus exposing the common biological basis of MPDs. 90 In addition, several of the genes involved in DNA replication initiation (MCM4, MCM10, GINS1, 91 GINS4, POLD1-2, POLE1-2), when disrupted, give rise to a syndromic combined immunodeficiency 92 (CID). Although clinically variable, these immunodeficiencies have in common that they are characterized by susceptibility to severe infections by herpes viruses and defects in the natural killer 93 (NK) cell compartment^{29–37}. 94

95

96 Here, we report that ATRIP deficiency, caused by homozygous splice variants in ATRIP, manifests with

97 features of MPD and immunodeficiency. The loss-of-function (LOF) *ATRIP* variants allow residual

ATR activity, although profoundly impaired. We performed a comprehensive analysis of the functional

99 impact of ATRIP loss on ATR signaling activity and delineated the accompanying downstream cellular

outcomes. In addition to genomic instability, patient-derived cells display an inadequate ATR response
 to genotoxic lesions, as evidenced by dysregulated cell cycle progression, increased chromosomal

101 to genotoxic lesions, as evidenced by dysregulated cell cycle progression, increased chromosomal 102 sensitivity, impaired proliferation, and pronounced decline in cell viability. Modeling of the *ATRIP*

sensitivity, impaired proliferation, and pronounced decline in cell viability. Modeling of the *ATRIP* variants by CRISPR-Select^{TIME} revealed reduced cell fitness³⁸. Our observations highlight a more

nuanced role of ATRIP within the ATR signaling pathway, clarify the biological basis of ATRIP-

105 mediated human disease, and expand the disease phenotype associated with ATRIP deficiency.

106 **RESULTS**

107 Personally identifiable patient information was redacted in accordance with medRxiv requirements.

108 Homozygous intronic ATRIP variants in patients with MPD and immunodeficiency

109 F1Pt was born at term, small for gestational age, and presented with severe microcephaly, developmental delay, and dysmorphic features (Supplementary Fig. 1a, b). Clinical investigations revealed failure to 110 thrive, growth retardation, grossly normal skeletal development, and a mild intellectual disability (ID). 111 112 Between the ages of 0-5, she developed severe varicella and recurring respiratory tract infections (RTIs). Laboratory investigations showed lymphopenia and intermittent neutropenia (Table 1). Whole exome 113 114 sequencing (WES) revealed a homozygous splice variant in intron 5 of the ATRIP gene (NM 13038.3): 115 c.829+5G>T (Chr3(GRCh38):g.48457421G>T), which was confirmed by Sanger sequencing (Fig. 1a and Supplementary Fig. 1c) Importantly, WES analysis of a large cohort of patients with microcephaly 116

- identified a male patient of North Indian ancestry (patient F46.1) with another homozygous splice
- variant in intron 5 of ATRIP $(c.829+2T>G)^{39}$. He presented with similar phenotypic features of facial
- dysmorphism, short stature, microcephaly, moderate ID, and recurrent RTIs (Supplementary Fig. 1a).
- 120 Finally, microcephaly and short stature has already been reported in a patient with reduced ATRIP
- 121 expression, due to defective splicing (patient CV1720)¹⁴. Reappraisal of patient CV1720's clinical status
- revealed a similar phenotype of late-onset lymphopenia and intermittent neutropenia (Table 1). More
- 123 detailed clinical information can be found in the case descriptions (Supplementary Materials and
- 124 Supplementary Table 1).

In silico tools predicted inactivation of the wild-type splice donor site near exon 5 for both variants
 (Supplementary Table 2). Analysis of the population database gnomAD v4.0.0 revealed absence of the

- 127 c.829+2T>G variant and presence of only five alleles of the c.829+5G>T variant, exclusively in a
- 128 heterozygous state in the European (non-Finnish) subpopulation (MAF: 0.0004369%). Eleven
- homozygous variants in *ATRIP* splice boundaries, identified in gnomAD v4.0.0 (Supplementary Table
- 3), were present with high allele frequencies (0.0001368% 56.0807635%) and showed exclusively low
- recall cutoff SpliceAI scores (recall cutoff <0.2; 0.00 0.18) (Supplementary Fig. 1d). Eight of the
- eleven homozygous variants were classified as benign (6/8) or likely benign (2/8) in ClinVar (Supplementary Table 3). Based on the clinical and genetic evidence presented above, *ATRIP* was
- 134 considered a plausible candidate gene for MPD and immunodeficiency.

135 ATRIP c.829+5G>T results in skipping of exon 5

136 To investigate the effect at the transcriptional level, reverse transcription PCR (RT-PCR) and Sanger 137 sequencing was performed in PHA blasts (Fig. 1b, c) and fibroblasts (Supplementary Fig. 1e) from F1Pt. 138 This failed to reveal a full-length transcript, but instead, showed presence of a transcript lacking exon 5 139 (Δ ex5, r.671_829del; p.(Ser224ArgfsTer2)) (Fig. 1d). In PHA blasts from her parents (F1Mo and F1Fa), 140 both the full-length and the shorter transcript were observed, in compliance with their zygosity (Fig. 1b and Supplementary Fig. 1f). The $\Delta ex5$ transcript was also detected in healthy control PHA blasts (3%) 141 and fibroblasts (6%), indicating the presence of a naturally occurring low-abundance isoform (Fig. 1b 142 and Supplementary Fig. 1e), consistent with the transcripts documented in the Ensembl genome browser 143 144 (ENST00000635082.1). We considered the possibility that c.829+5G>T represents a leaky splice 145 variant, however, based on targeted RNA sequencing (Supplementary Fig. 1g), RT-PCR 146 (Supplementary Fig. 1h), and reverse transcription quantitative PCR (RT-qPCR) (Supplementary Fig. 147 1i), we found no evidence supporting this. Although aberrant splicing arising from c.829+2T>G was not investigated, the consequences of c.829+2T>G are expected to coincide with c.829+5G>T as it 148

149 inactivates the consensus splice donor site in intron 5, demonstrated by the *in silico* splice prediction

150 tools (Supplementary Table 2).

151 Reduced ATR protein in absence of full-length ATRIP

152 Alternative splicing of ATRIP pre-mRNAs harboring c.829+5G>T or c.829+2T>G variants results in Δ ex5 and a subsequent shift of the reading frame (r.671_829del). At the amino acid level, this translates 153 into a serine to arginine substitution at position 224, immediately followed by the premature stop codon 154 155 TAG (p.(Ser224ArgfsTer2)) (Fig. 1d). Using western blot, we confirmed absence of full-length ATRIP 156 in both fibroblasts and Epstein-Barr virus immortalized lymphoblastoid cell lines (EBV-LCLs) of F1Pt (Fig. 1e and Supplementary Fig. 1j, k). In absence of full-length ATRIP, ATR expression was strongly 157 reduced in both cell types, while parental LCLs from F1Fa showed an approximately 50% reduction in 158 159 both ATR and ATRIP protein levels. In line with the presumed co-dependency of ATRIP and ATR, fibroblasts from an ATR patient (F02-98)¹² exhibited strongly reduced ATRIP levels (Fig. 1e and 160 Supplementary Fig. 1k). In contrast, expression levels of interaction partners RPA1 and TOPBP1 were 161

162 undisturbed by the absence of ATRIP (Fig. 1e and Supplementary Fig. 1j, k).

163 Mutant ATRIP is loss-of-function

The premature translation stop as a consequence of $\Delta ex5$ is anticipated to trigger nonsense-mediated 164 mRNA decay (NMD). When abolishing NMD using puromycin, equal quantities of both $\Delta ex5$ (±380bp, 165 51%) and full-length (±538bp, 49%) amplicons were observed in cDNA from EBV-LCLs of F1Fa (Fig. 166 1f). However, in absence of puromycin, half of the $\Delta ex5$ transcript persisted (±380bp, 36% vs ±538bp, 167 64%), indicating that the Δ ex5 transcript resulting from c.829+5G>T might translate into a truncated 168 protein. Due to the unavailability of high-quality antibodies targeting the N-terminal region of ATRIP, 169 170 we confirmed the presence of a truncated protein by overexpressing 3xFLAG-tagged wild type (wt) or mutant (mut) ATRIP, which resulted in a stable 82kDa and 37kDa protein, respectively (Fig. 1h). 171 172 According to the remaining amino acid sequence (AA1-224), this 37kDa ATRIP protein contains both 173 the coiled-coil and RPA binding motif but lacks the TOPBP1 and ATR binding domains (Fig. 1g)⁴⁰. To 174 assess this, HEK293T cells were co-transfected with ATR-V5, RPA1-Myc, and the 3xFLAG-wtATRIP 175 or 3xFLAG-mutATRIP constructs. Upon pulldown with an anti-FLAG antibody, immunoblotting 176 confirmed that the 37kDa mutant was able to interact with RPA1, in accordance with earlier mutational studies^{41–43}. No ATR protein could be visualized, indicating an abolished interaction. Faint TOPBP1 177 was detected, but at levels comparable to those of the IgG controls, suggestive of a defective interaction 178 179 with TOPBP1 (Fig. 1h).

180 ATRIP c.829+5G>T is associated with CD4⁺ T, B, and NK lymphopenia and progressive 181 neutropenia

Given the features of immunodeficiency in patients with ATRIP deficiency, we set out to characterize 182 the immunophenotype of F1Pt. In line with the RTIs and a severe varicella-zoster infection, F1Pt 183 184 presented with reduced numbers of B and NK cells (Fig. 2a and Table 1). Low numbers of CD4⁺ T cells and an inverted CD4⁺/CD8⁺ ratio were noted (Fig. 2a and Table 1). These features were unique to F1Pt, 185 as both the heterozygous parents and the wild-type sister had immune profiles similar to healthy controls 186 (HCs) (Fig. 2b). Immunoglobulin substitution therapy related to IgG2 subclass deficiency and a specific 187 pneumococcal antibody deficiency, along with azithromycin maintenance, effectively controlled the 188 RTIs (Fig. 2c and Table 1). Over time, F1Pt developed a progressive neutropenia in presence of 189 190 antineutrophil cytoplasmic antibodies, which was responsive to emergency granulopoiesis during acute 191 infections (Fig. 2d). Between the ages of 16-20, F1Pt presented with recurrent autoimmune hemolytic

192 anemia (AIHA) that subsided upon treatment with corticosteroids and anti-CD20 monoclonal antibody

193 (mAb) treatment (Fig. 2e).

194 Expansion of T effector cells, low levels of CD16⁺ NK and absent MAIT, and iNKT lineages

195 To study the impact of ATRIP deficiency on the lymphocyte compartment in more detail, we performed high-parametric flow cytometry (FCM) (Fig. 2f, g) on PBMCs of F1Pt and age-matched HCs. Among 196 197 the CD4⁺ and CD8⁺ T cells in F1Pt, we noted expansion of effector cells at the expense of naïve T cells 198 (Fig. 2f). Especially in the CD8⁺ T cell compartment, increased percentages of HLA-DR⁺ and CD27⁻ 199 CD28⁻ T cells were noted, indicating ongoing activation and exhaustion. Similarly, CD95⁺ double-200 negative (DN) T cells were expanded. In addition to diminished naïve T cell levels, we noted the absence of both mucosal-associated invariant T (MAIT) and invariant natural killer T (iNKT) cells. The observed 201 202 NK lymphopenia was characterized by a selective reduction of CD16⁺ NK cells (Fig. 2f). NK cytotoxic 203 potential was assessed and revealed normal CD107a upregulation upon stimulation with K652. In line 204 with the higher proportion of CD56^{bright} NK cells in F1Pt, perforin expression was reduced (data not shown). In a similar approach, the B cell and innate compartment was investigated in detail (Fig. 2g). 205 CD21^{lo} B cells were expanded in F1Pt at the expense of CD21^{hi} memory B cells and plasmablasts. In 206 207 the innate compartment, we noted lower percentages of type 1 dendritic cells (DC1) and plasmacytoid 208 (p)DCs. Among monocyte subsets, both inflammatory and CD169⁺ expressing monocyte subsets were 209 increased. Manual gating of the FCM data confirmed the main findings of this analysis (Supplementary 210 Fig. 2a-c).

211 TCR oligoclonality and altered antibody class switch recombination in absence of ATRIP

212 Given the diminished levels of naïve T cells and absence of MAIT cells in F1Pt, we looked for potential

- 212 disparities in the recombinational processes of antigen receptors. To study this in more detail, CITE-seq
- 214 (cellular indexing of transcriptomes and epitopes by sequencing) combined with T cell receptor (TCR)
- and B cell receptor (BCR) sequencing of PBMCs, collected prior to anti-CD20 mAb treatment, was
- 216 performed. CITE-seq profiling confirmed the observed immune defects (Fig. 3a, and Supplementary
- Fig. 3a). By visualizing both the usage and pairing of unique *TRAV* and *TRBV* genes, we observed a decreased diversity in the TCR repertoire in F1Pt compared to HCs (Fig. 3b, c and Supplementary Fig. 3b, c). Oligoclonality was most evident in CD8⁺ effector memory (T_{EM}) cells, suggesting clonal
- expansion (Fig. 3b, c). Using a similar analysis based on *IGH* transcripts, we observed no restrictions in
- 221 BCR repertoire diversity (Supplementary Fig. 3e, f). Changes in complementarity-determining region 3
- 222 (CDR3) length and composition have been described in immunodeficiencies^{44,45}. Comparing the CDR3
- 223 length profiles of *TRAV*, *TRBV*, and *IGH* transcripts, we observed no consistent differences between
- F1Pt and HCs (Fig. 3d and Supplementary Fig. 3d, g). These findings are indicative of competent V(D)J
- recombination, suggesting adequate repair by non-homologous end-joining (NHEJ) in the absence of
- ATRIP.
- 227 Affinity maturation and isotype switching of antibodies require efficient DNA recombination processes
- called somatic hypermutation and class switch recombination (CSR), respectively. A potential role for ATR signaling in CSR has been suggested in previous studies, owing to its regulatory function in DNA
- replication and proliferation^{15,46,47}. Using a modified version of linear amplification-mediated high-
- throughput genome-wide translocation sequencing (LAM-HTGTS), we assessed CSR patterns in
- ATRIP deficient PBMCs^{48,49}. Our results revealed an altered isotype switching profile in F1Pt, with
- decreased proportions of recombination between $S\mu$ and $S\gamma1$, $S\gamma2$, and $S\gamma4$ (Fig. 3e). A marked increase
- in inversional S μ -S γ 1 and S μ -S γ 4 junctions was noted, indicating reduced efficiency in IgG subclass
- switching (Fig. 3f). We observed increased usage of longer microhomologies (≥ 10 bp) at the Sµ-Sα
- switch junctions in F1Pt as compared to HCs (Fig. 3g), indicating increased repair via alternative end

joining. Given that alternative end joining depends on DNA end resection during early S phase, these
 results are suggestive of disruptions in cell cycle dynamics⁵⁰.

ATRIP c.829+5G>T presents with a DNA repair signature and interferon-driven immune dysregulation

We performed Gene Set Enrichment Analysis (GSEA) to examine the differentially expressed genes in 241 242 PBMCs of F1Pt compared to HCs. Among the most altered biological processes (adj P < 0.05; Log2: ± 1), 243 we noted a distinct DNA repair signature in PBMCs from F1Pt (Fig. 4a, b and Supplementary Fig. 4a, 244 b), which was also evident in both T effector and NK subsets (Supplementary Fig. 4c, d). Likely related 245 to F1Pt's autoimmune phenotype, an upregulated interferon (both type I and II) response was observed. 246 Analysis of cytokine expression in serum samples collected during an episode of AIHA and after 247 successful treatment with anti-CD20 mAb confirmed increased interferon signaling (IFNy and IP10) 248 and indicated both innate and T lymphocyte subset activation (IL-10, IL-18, IL-27, IL-31) (Fig. 4c). 249 While treatment of AIHA with corticosteroids and anti-CD20 mAb resulted in partial reduction of all cytokines, the Th2-signature cytokines IL-10 and IL-31 persisted. FCM analysis confirmed the response 250 251 to anti-CD20 mAb therapy, with partial normalization of interferon-regulated proteins CD64 and CD169 252 on classical monocytes (Fig. 4d). While effectively targeting B cells, anti-CD20 mAb treatment did not normalize NK and T cell subset percentages, nor did it normalize T cell maturation (Supplementary Fig. 253 254 4e-g). Additionally, treatment had minimal effect on T cell activation, as indicated by increased levels 255 of ICOS, OX40, and PD1 (Supplementary Fig. 4h).

256 Impaired T cell proliferation in absence of ATRIP

257 Considering that GSEA and CSR analyses indicated dysregulated DNA repair and cell cycle dynamics 258 in F1Pt cells, we proceeded to investigate the proliferative capacity of T cells in more detail. The 259 lymphocyte transformation test (LTT) performed on whole blood of F1Pt revealed reduced or absent T cell proliferation upon stimulation with both mitogens and specific antigens (candida, tetanus), 260 respectively (Fig. 4e). Using a more comprehensive study determining both the precursor frequency 261 (PF) and proliferation index (PI) of CellTrace Violet (CTV) labeled T cells, we noted a substantial 262 263 reduction in the proliferation capacity of both CD4⁺ and CD8⁺ T cells of F1Pt upon stimulation with the mitogen PHA (Fig. 4f). In conclusion, the immunophenotype of ATRIP deficiency is characterized by 264 defects in all three lymphocytic lineages, an interferon-driven immune dysregulation, and a profound T 265 266 cell proliferative defect.

267 Loss of ATRIP does not impair ATR recruitment and auto-phosphorylation

268 Next, we set out to characterize the molecular processes driving disease in absence of ATRIP. As 269 localization of ATR to DNA damage sites is a prerequisite for ATR activation, we assessed nuclear ATR 270 foci by immunofluorescence. Unexpectedly, this revealed that F1Pt fibroblasts were competent in forming ATR foci in response to the known ATR-activating DNA damage inducers mitomycin C 271 272 (MMC), a DNA interstrand crosslinker (ICL), UV, and ionizing radiation (IR). In addition, F02-98 273 fibroblasts (ATR patient) showed normal recruitment of ATR (Fig. 5a and Supplementary Fig. 5a), 274 despite substantially reduced total ATR protein levels (11% of HC levels; Supplementary Fig. 1g). No 275 significant differences in foci number per cell were observed between HC and F1Pt fibroblasts following 276 MMC and IR treatment, whereas UV exposure resulted in a slightly higher amount of ATR foci in F1Pt 277 and F02-98 fibroblasts. The higher number of spontaneous foci in mock conditions suggests persistent 278 DNA damage (Fig. 5a and Supplementary Fig. 5a).

Next, ATR-dependent substrate phosphorylation was investigated as a measure for ATR activation.
 Autophosphorylation of ATR on residue T1989 has been identified as a hallmark of its active state and

is regulated by DNA damage induction^{51,52}. T1989 phosphorylation (hereafter referred to as pATR) was 281 readily detected in untreated F1Pt and F02-98 cells and further increased upon UV treatment, although 282 283 absolute pATR levels were reduced compared to control fibroblasts (Fig. 5b and Supplementary Fig. 5b). Interestingly, when expressing UV-induced pATR levels as a fold increase over basal levels, a 284 similar 1.5-fold induction was observed for F1Pt, F02-98, and control cells (Fig. 5c). Of note, the 285 specificity for T1989 phosphorylation was confirmed using lambda phosphatase (λ PPase) treatment 286 (Supplementary Fig. 5c). Full activation of CHK1, the major downstream effector of the ATR signaling 287 pathway, requires phosphorylation by ATR⁶. Following UV exposure, CHK1 phosphorylation on 288 residue S317 (indicated as pCHK1) was reduced in both F1Pt and F02-98 fibroblasts compared to HCs 289 290 (Fig. 5b and Supplementary Fig. 5b). This reduction was also evident when the fold induction over basal 291 levels was quantified (Fig. 5c). Of note, total CHK1 levels were reduced in F02-98, but not in F1Pt 292 fibroblasts (Fig. 5b), a possible consequence of the high passage number and senescence of the F02-98 cells⁵³. 293

294 DNA repair intermediates formed after UV irradiation trigger H2AX phosphorylation at S139 (known

as γ H2AX), a process mainly mediated by ATR and found to be impaired in ATR patient cells^{12,15,54,55}.

- Following UV exposure, a strong pan-nuclear γ H2AX positivity was readily noted via immunofluorescence in control fibroblasts (Fig. 5d). In contrast, γ H2AX was almost entirely absent in
- EdU- nuclei of F1Pt fibroblasts, while it was retained in EdU+ nuclei. Consistent with this, FCM
- 299 analysis of γ H2AX expression in EdU- cells showed decreased MFI values in F1Pt (Fig. 5e). In 300 conclusion, while the exact mechanism of ATR recruitment and activation remains unclear, our
- 301 observations indicate that ATRIP is dispensable for the initial recruitment and subsequent
- autophosphorylation of ATR. Downstream ATR substrate phosphorylation was impaired but notabolished, providing evidence for an inadequate ATR signaling response in absence of ATRIP.

304 Compromised replication stress response and cell cycle progression in absence of ATRIP

Replication stress induces stalling of replication forks and exposes single-stranded DNA (ssDNA) that is rapidly coated with RPA. Subsequent ATR activation safeguards genomic stability and prevents further fork stalling and collapse by restraining fork progression and suppressing origin firing. In addition, the ATR kinase is responsible for stabilizing stalled forks, thereby facilitating fork restart upon resolved stress. We aimed to thoroughly define the *in vitro* phenotype associated with ATRIP deficiency by investigating the cellular consequences of genotoxic treatments.

- 311 Previous studies noted comparable cell cycle distributions in untreated cells of ATR patients and HCs^{14,15}. Consistent with this, we observed no differences in cell cycle ratios between F1Pt and control 312 313 fibroblasts or PHA blasts (Fig. 6a, b and Supplementary Fig. 6a). To investigate the replication stress 314 response, we treated F1Pt fibroblasts with MMC and assessed the replicative response using FCM (Fig. 315 6a). Whereas HC cells efficiently suppressed origin firing and fork progression upon MMC treatment 316 (indicated by reduced EdU intensity), F1Pt cells showed no substantial response (Fig. 6c). To verify 317 ATR involvement, we pretreated cells with an ATR inhibitor (ATRi). Upon ATRi treatment, the EdU intensity of HC cells mimicked that of ATRIP deficient cells, confirming impaired ATR signaling in 318 319 F1Pt cells. Additionally, DAPI histograms of S phase cells showed accumulation of HC cells in late S 320 phase following MMC, in contrast to F1Pt cells that retained a diffuse DAPI profile similar to non-321 treated cells.
- In absence of timely ATR activation, excessive origin firing results in accumulation of RPA-ssDNA nucleoprotein filaments, progressively depleting the nuclear pool of RPA and preceding compromised
- fork integrity⁵⁶. Using immunofluorescence, we observed significantly higher RPA2 intensity in S phase
- 325 F1Pt fibroblasts compared to HCs, both in mock and upon hydroxyurea (HU) treatment (Fig. 6d and

326 Supplementary Fig. 6b). HU induces widespread fork stalling through dNTP depletion, as evidenced by

327 the complete loss of EdU incorporation after 3h of HU treatment (Supplementary Fig. 6c)⁵⁷. Additional treatment with ATRi further increased RPA2 intensity in both F1Pt and HCs, although the RPA2 328

329 intensity levels in HCs did not reach those observed in F1Pt.

330 Next, we determined whether patient fibroblasts retained their ability to recover from acute HU-induced 331 replication stress. While HC cells readily resumed DNA synthesis, F1Pt fibroblasts demonstrated 332 reduced levels of fork recovery following replication fork stalling, indicated by decreased EdU 333 incorporation following HU release. Combined HU and ATRi treatment impeded replication recovery 334 in HC cells and further intensified the observed impairment in F1Pt cells (Fig. 6e).

- Regulation of cell cycle progression is crucial to allow repair of damaged DNA and completion of DNA 335 336 replication prior to mitosis. Pronounced G2/M arrest has been described as a hallmark of ATR deficiency, reflecting the direct consequence of acquired DNA damage during the S phase⁵⁶ 337 Accordingly, F1Pt fibroblasts and PHA blasts accumulated in the G2/M phase after MMC exposure 338 339 (Fig. 6f and Supplementary Fig. 6a). ATRi treatment in HC cells resulted in similar checkpoint 340 activation, confirming that the observed G2/M arrest is a direct result of defective ATR signaling in the 341 S phase (Fig. 6f). An additional established function of ATR is the G2/M checkpoint activation in 342 response to IR, preventing premature mitotic entry in the presence of severely damaged DNA (Supplementary Fig. 6d)^{58,59}. In ATRIP deficient cells, the ATR signaling pathway retained sufficient 343 activity to initiate G2/M checkpoint arrest upon irradiation, albeit at a significantly lower level compared 344 345 to HC cells. (Supplementary Fig. 6d).
- As our data did not indicate significant deviations in the cell cycle distribution of unperturbed patient 346
- cells, we extended our investigations to assess the S phase kinetics using an EdU pulse-chase assay (Fig. 347
- 348 6g and Supplementary Fig. 6e)⁶⁰. We found that unperturbed F1Pt PHA blasts displayed a prolonged S
- phase, compared to HC cells. Exposure to MMC and UV increased the S phase-delay in both F1Pt and 349
- HC cells, with a more pronounced effect in F1Pt cells. In light of these findings, we speculated that 350
- 351 proficient ATR signaling is essential for facilitating T cell proliferation under conditions of excessive
- 352 replicative stress. Indeed, upon treatment with MMC, we observed a strongly diminished proliferative
- 353 response and subsequent division rate of CTV-labeled T cells of F1Pt (PF and PI, respectively),
- particularly in CD4⁺ T cells (Fig. 6h and Supplementary Fig. 6f). 354
- 355 Taken together, defective ATR signaling in ATRIP deficient cells results in an impaired replication 356 stress response, consequently compromising cell cycle progression and proliferation.

ATRIP c.829+5G>T cells display DNA damage, chromosomal sensitivity, and impeded survival 357

The consequences of compromised replication and subsequent accumulation of DNA damage typically 358 359 manifest post-mitosis, resulting in chromosomal breakage and cell death. To assess spontaneously 360 occurring DNA damage, we examined the formation of γ H2AX nuclear foci, a well-established marker 361 of DNA double-strand breaks (DSBs). Quantification of YH2AX in EdU- cells revealed a significantly higher number of foci in F1Pt and F02-98 fibroblasts (Fig. 7a and Supplementary Fig. 7a). To evaluate 362 DSB repair fidelity, we analyzed micronucleus (MN) formation using 3 different assays: the G0 MN 363 assay, the MMC MN test, and a newly developed S MN assay (Fig. 7b). F1Pt PHA blasts showed 364 increased spontaneous MN levels with the S MN assay, opposed to the normal levels observed with the 365 G0 MN test (Fig. 7c). This discrepancy suggests that DNA damage and subsequent chromosomal 366 breakage only becomes apparent after multiple cell cycles have been completed. Correspondingly, 367 368 immunofluorescence preparations of proliferating fibroblasts showed higher MN frequencies in F1Pt

369 and F02-98 compared to HCs (data not shown). 370 Next, we assessed chromosomal sensitivity to IR and MMC. No increase in radiation-induced MN yields

- 371 was observed in F1Pt PHA blasts with the G0 MN assay, indicating a proficient NHEJ DSB repair pathway. Irradiation during the S phase led to a higher yield of MN (Fig. 7d and Supplementary Fig.
- 372 373 7b), highlighting a specific S phase sensitivity to radiation in absence of ATRIP, a phenotype not earlier
- associated with cells deficient in ATR signaling^{12,61}. As anticipated, F1Pt cells also showed impaired 374
- ICL repair, reflected by the increase in MN formation in the presence of MMC (Fig. 7d). No increase in 375
- 376 MN levels was detected in PHA blasts of the parents using both the MMC and S MN assay (Fig. 7c, d
- 377 and Supplementary Fig. 7b), indicating that the heterozygous presence of the c.829+5G>T variant does
- 378 not compromise ATR signaling.
- 379 Notably, persistent DNA damage accumulated during unperturbed replication in F1Pt and F02-98 380 fibroblasts negatively affected cell survival (Fig. 7e, g). In addition, we meticulously quantified cell 381 death and cell proliferation in absence of functional ATR signaling following DNA damage induction 382 by MMC, UV, or IR (Fig. 7f-i and Supplementary Fig. 7e, f). Treatment with 0.2 µg/ml MMC and 20
- 383 J/m² UV revealed a profound sensitivity of F1Pt and F02-98 fibroblasts, whereas cell survival of control 384 fibroblasts was slightly impaired by MMC and unaffected by UV (Fig. 7g). These results confirm the
- previously described MMC and UV hypersensitivity in absence of functional ATR signaling^{12,15,61}. In
- 385 line with the G0 and S MN assay results of PHA blasts, exposure to 10 Gy IR only elicited a slight
- 386 increase in cell death in F1Pt and F02-98 fibroblasts (Fig. 7g). Combined treatment of ATRi and a DNA 387
- 388 damage inducer progressively compromised cell survival. Although minor in the case of F1Pt and F02-
- 389 98 fibroblasts, this increase was consistently observed for all three genotoxic treatment conditions,
- 390 suggesting residual ATR kinase activity (Fig. 7h).
- 391 In contrast to F1Pt and F02-98 fibroblasts, the combined treatment of ATRi with genotoxic stressors 392 profoundly impaired cell survival in HC fibroblasts (Fig. 7h). To assess redundancy with the other DDR 393 kinases, we quantified cell death rates in the presence of specific inhibitors targeting ATM and DNA-394 PKcs. ATM inhibition (ATMi) resulted in particularly high lethality in combination with ATRIP 395 deficiency (F1Pt) or hypomorphic ATR variants (F02-98), contrasting with the response observed in HC fibroblasts (Fig. 7h and Supplementary Fig 7d). This was most evident upon IR-induced genotoxic 396 397 stress, implying a substantial redundancy between the ATR and ATM kinase. Concomitant DNA-PK 398 inhibition with genotoxic treatment did not evoke additional sensitivities in F1Pt, F02-98, or HC 399 fibroblasts (Supplementary Fig. 7c, d). In conclusion, these findings demonstrate that loss of ATRIP 400 results in chromosomal sensitivity and compromised cell viability, although some residual ATR 401 signaling was retained. Moreover, concurrent ATM kinase activity is needed to mitigate the most detrimental effects of genotoxic stressors, as previously suggested for ATR deficient cells^{15,61}. 402

Modeling of ATRIP variants by CRISPR-Select^{TIME} exposes reduced cell fitness 403

Finally, to confirm the impact of the c.829+5G>T and c.829+2T>G ATRIP variants in an independent 404 cellular model, cell fitness was assessed using the CRISPR-Select^{TIME} methodology³⁸. To accurately 405 study the effects of these variants, an MCF10A cell line harboring only one functional ATRIP or ATR 406 407 allele was generated (Fig. 8a and Supplementary Fig. 8a). In addition to the variants identified in this study, a hypomorphic leaky splice variant in ATR (c.2022A>G, homozygous in F02-98¹²), the proposed 408 causal ATRIP variants identified in patient CV1720¹⁴ (c.2278C>T and c.248-14A<G), and a 409 homozygous benign ATRIP splice variant present in gnomAD v4.0.0 (c.2056-6_2056-3del) were 410 modeled. As expected, the presence of the c.2022A>G ATR variant resulted in strongly reduced cell 411 fitness (Fig. 8b). CRISPR-Select^{TIME} revealed similarly large effect sizes for both ATRIP splice variants, 412 413 c.829+5G>T (homozygous in F1Pt) and c.829+2T>G (homozygous in F46.1). Moreover, we confirmed 414 the anticipated neutrality of the homozygous ATRIP variant reported in gnomAD v4.0.0 (c.2056-

415 6_2056-3del). Surprisingly, for the reported ATRIP variants of patient CV1720, reduced fitness was 416 only evident for the c.2278C>T variant. Although abnormal splicing was observed in presence of the second ATRIP allele of patient CV1720, we were unable to validate the causality of the candidate variant 417 c.248-14A>G using CRISPR-Select^{TIME} (Fig. 8c and Supplementary Fig. 8b), which might reflect the 418 originally reported hypomorphic nature of this variant¹⁴. Given the role of both ATR and ATRIP in 419 regulating DNA replication and proliferation dynamics, application of the CRISPR-420 Select^{TIME} methodology in a mono-allelic ATRIP cell line appeared particularly suitable to establish the 421 422 pathogenic role of the identified ATRIP variants c.829+5G>T and c.829+2T>G, next to the known 423 c.2278C>T variant. Moreover, frequencies of these variants and their corresponding internal controls 424 (frameshifts) were strikingly comparable, indicating similar selection against both editing outcomes

425 (Fig. 8c and Supplementary Fig. 8b).

426 **DISCUSSION**

427 In this study, we demonstrated that biallelic loss-of-function (LOF) *ATRIP* variants result in human

428 disease, characterized by short stature, microcephaly, intellectual disability, and immunodeficiency. The

429 causal role of the pathogenic *ATRIP* variants is supported by multiple lines of evidence; (1) the presence

430 of homozygous novel or rare variants with a similar LOF consequence on protein level in two patients 431 of independent ancestry, (2) the complete absence of homozygous LOF *ATRIP* variants in the non-

- 432 affected population (cfr. gnomAD), (3) the finding of an impaired replication stress response associated
- 433 with disturbed proliferation and survival in primary patient cells, and (4) reduced cell fitness when
- 434 introducing these variants in an independent cellular model.

Ablation of ATR, TOPBP1, or CHK1 in murine models has consistently resulted in embryonic lethality,

436 emphasizing the essential nature of the ATR signaling pathway^{7,8,59,62,63}. This is further illustrated by the 437 identification of exclusively hypomorphic *ATR* mutations in patients with microcephalic primordial

438 dwarfism (MPD)^{12,14-16}. In a similar vein, it has been suggested that ATRIP deficiency would be

439 incompatible with life. However, our study demonstrates that LOF *ATRIP* variants are tolerated to some

440 extent in human individuals, albeit resulting in a severe MPD phenotype. In line with our findings,

440 extent in numan multiduals, abert resulting in a severe fur D phenotype. In the with our midnigs, 441 knock-out *atrip* zebrafish were also shown to be viable but displayed a severely compromised body

- 442 length and lifespan, suggesting a crucial role of *atrip* in growth and development during the juvenile
- 443 stage⁶⁴.

ATRIP plays a crucial role in facilitating stabilization, recruitment, and activation of the ATR 444 kinase^{11,40,65}. Studies using both cellular models and patient cells have shown that partial or complete 445 ATRIP loss results in a significant reduction in ATR protein levels^{11,14,41}. This co-dependency between 446 ATR and ATRIP for protein stability is further evidenced by our data, showing markedly diminished 447 ATR levels in complete absence of ATRIP. Several lines of evidence have demonstrated that ATRIP 448 449 acts as a sensor of RPA-ssDNA nucleoprotein filaments, promoting ATR recruitment and subsequent activation of downstream substrates^{17,65}. Interestingly, an early mutational study detected efficient 450 451 CHK1 phosphorylation in the presence of mutated ATRIP devoid of its RPA-binding domain⁴¹. 452 Correspondingly, our findings revealed that the remaining pool of ATR was able to form foci and 453 autophosphorylate (T1989 phosphorylation) upon exposure to genotoxic stressors in absence of ATRIP, although at lower levels. These results suggest that ATRIP is required for ATR stability but not for ATR 454 recruitment and activation. While both TOPBP1 and ETAA1 are able to activate ATR, only the ATR-455 TOPBP1 axis requires ATRIP for recruitment to RPA-ssDNA filaments^{17,22,40}. It remains to be clarified 456 whether binding and activation of ATR by ETAA1 is retained upon ATRIP loss. We speculate that 457 interactions with ETAA1 and potentially other unanticipated complex partners may underly the ability 458 459 of ATR to recognize DNA damage and display kinase activity in an ATRIP-independent manner.

Studies using murine models have provided compelling evidence implicating ATR signaling in the 460 development, maturation, and maintenance of the immune system^{66–70}, an association which had not 461 462 been clearly described in humans to date. These mice consistently presented with developmental abnormalities analogous to MPD and features of premature ageing, demonstrating that unresolved 463 replicative stress, proliferative failure, and cellular senescence likely underly both the developmental 464 and immunological phenotype. The association of MPD with immunodeficiency is further supported by 465 an emerging class of inborn errors of immunity (IEI) linked to monogenic defects in DNA replication 466 factors^{29,31–34,71}. These disorders typically present a combination of immunodeficiency with perturbed 467 growth, microcephaly, progeroid features, and developmental abnormalities. All three ATRIP patients 468 469 had clinical features suggestive for immunodeficiency, and the immunophenotype - characterized by 470 lymphopenia and neutropenia - draws intriguing parallels to observations in other DNA replication-471 associated disorders. Our data revealed that ATRIP loss compromises the replication stress response,

472 leading to a DNA repair signature in immune cells in vivo and impaired lymphocyte proliferation in 473 vitro. Despite our observations in ATRIP deficient patients, no definite immunological phenotype has been observed in patients with biallelic ATR mutations (based on personal correspondence with 474 respective clinicians). Although Mokrani-Benhelli et al.¹⁵ noted minor immune irregularities in a 9-year 475 old patient with biallelic ATR mutations, drawing parallels to our patient F1Pt, the phenotype was 476 477 relatively mild and no up-to-date immunological data could be obtained. Several explanations for these 478 disparate observations are possible; (1) the hypomorphic nature of the ATR mutations may mitigate the impact of ATR deficiency on the human immune system, (2) ATR signaling in immune cells such as 479 lymphocytes is critically dependent on ATRIP, (3) ATRIP has ATR-independent functions in the human 480 481 immune system. In line with this, considerable heterogeneity in immunological features is also observed in both DNA repair and DNA replication-associated IEI, highlighting that mutations within the same 482 cellular processes can lead to diverse phenotypes^{31,32,71,72}. Finally, several older studies reported 483 484 immunological abnormalities, such as pancytopenia, in patients with a phenotypical diagnosis of Seckel syndrome^{73–76}. It is worth noting, however, that the molecular causes of Seckel syndrome had not yet 485 been identified at that time, potentially leading to misdiagnoses due to overlapping features with other 486 MPD-like disorders^{77,78}. More studies, comprehensively describing the immunological phenotype in 487 molecularly characterized disorders of DNA replication and DNA repair, will be required to further our 488 489 understanding of the role of ATR and ATRIP in the biology of immune cells.

490 In summary, our study provides evidence supporting ATRIP as a disease-associated gene in MPD and 491 IEI and offers valuable insights into the cellular and immunological characteristics. Our findings 492 challenge the conventional paradigm of the ATR-ATRIP interaction, underscoring the need for further 493 investigation into the molecular mechanisms governing ATR activation upon DNA damage. Although 494 our data suggests an essential role for ATRIP in safeguarding immune cells against the consequences of 495 unresolved replicative stress, it remains unclear whether this reflects an unidentified noncanonical 496 function of ATRIP or this is mediated by the ATR signaling pathway. Careful clinical monitoring and 497 additional research are needed to further delineate the phenotypic spectrum associated with both biallelic 498 ATR and ATRIP mutations and to better understand the cellular mechanisms driving the immunological

499 phenotype.

500 MATERIAL AND METHODS

501 Study approval

502 Ethical approval for this study was granted by the ethics committee of Ghent University Hospital in 503 Belgium (2012/593 and 2019/1565). Clinical data and samples were collected with informed consent 504 from the participants of the study, in accordance with the 1975 Helsinki Declaration.

505 Cell culture

506 Lymphoblastoid cell lines (LCLs) were derived from blood following EBV transformation. LCLs were 507 maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with GlutaMAX, 10% FBS (Bodinco and Tico Europe), 1% penicillin-streptomycin (10,000 U/mL; Gibco), 1 mM sodium 508 509 pyruvate (Gibco) and 50 µM 2-mercaptoethanol (Gibco). PHA blasts were generated by culturing cryopreserved isolated peripheral blood mononuclear cells (PBMCs) in LCL medium supplemented 510 with 2% phytohemagglutinin-M (PHA-M; Gibco). HEK293T cells (The American Type Culture 511 512 Collection (ATCC)) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin (10,000 U/ml), 2mM GlutaMAX (Gibco). Primary human 513 514 dermal fibroblast cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin-515 streptomycin (10,000 U/ml), 2mM GlutaMAX, 0.1 mM sodium pyruvate, and 50 µM 2-516 mercaptoethanol. MCF10A cells (ATCC; CRL-10317) were cultured in Dulbecco's Modified Eagle 517 Medium:Nutrient Mixture F-12 (DMEM / F-12) (Thermo Fisher Scientific; 31330038), supplemented with 5% horse serum (Thermo Fisher Scientific; 16050122), 1% Penicillin/Streptomycin (Thermo 518 519 Fisher Scientific; 15070063), 10 µg/ml insulin (Sigma-Aldrich; I1882), 0.5 µg/ml hydrocortisone 520 (Sigma-Aldrich; H0888-1G), 20 ng/ml EGF (Peprotech; AF-100-15), and 100 ng/ml cholera toxin 521 (Sigma-Aldrich; C8052-5MG). ATR deficient fibroblasts from a previously described ATR patient (F02-98) were purchased from Coriell institute (GM18366)¹². All cell lines were incubated at 37°C with 522 523 5% CO₂.

524 Sequencing analysis

Trio whole exome sequencing (WES) on genomic DNA of the patient and unaffected parents was performed using KAPA HyperExome probes (Roche). Paired-end massive parallel sequencing was performed on a NovaSeq 6000 Instrument (Illumina). Data analysis was performed on an in-house developed platform, in accordance with the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) guidelines⁷⁹. Variant confirmation and segregation analysis was performed by Sanger Sequencing on an ABI 3730 platform (Applied Biosystems).

RNA for evaluation of aberrant splicing was obtained using the Maxwell® RSC simplyRNA Tissue Kit
on a Maxwell® RSC Instrument (Promega Corporation) from PHA blasts stimulated with 1 μl/ml PHAM and 50 μl/ml interleukin-2 (IL-2) (Sigma-Aldrich), LCLs, and patient-derived dermal fibroblasts.
cDNA was synthesized using Superscript III Reverse Transcriptase (Invitrogen) according to
manufacturer's recommendations. Amplicon length analysis was performed using a TapeStation
(Agilent Technologies) or an ABI 3730 platform (Applied Biosystems).

Targeted RNA-sequencing was performed with the SureSelectXT HS2 RNA System kit (Agilent
 Technologies) using SureSelectXT Human All Exon V7 probes (Agilent Technologies) for target
 enrichment and sequencing was performed on a NovaSeq 6000 Instrument (Illumina).

All primers were purchased from Integrated DNA Technologies and are listed in Supplementary Table
5. Nucleotide and protein numbering is in accordance with transcript ENST00000320211 and
NM 000057.3, respectively.

544 RT-qPCR

545 Fibroblasts from healthy controls and patient F1Pt were lysed in RLT buffer (Oiagen) and stored at -546 80°C until further processing. RNA was purified using the RNeasy Mini kit (Qiagen) according to 547 manufacturer's protocol. Total RNA was reverse transcribed into cDNA using the SensiFast cDNA 548 Synthesis Kit (Bioline) and real-time quantitative PCR (RT-qPCR) was performed using the 549 LightCycler 480 (Roche). Gene transcript levels were normalized against an endogenous B-actin control. Samples were run in duplicates in two independent experiments. Results are depicted as the 550 relative expression compared to the healthy controls, determined using the $2^{-\Delta\Delta Ct}$ method. To determine 551 mRNA expression levels of a shorter mutant transcript and a transcript containing exon 5 in F1Pt 552 fibroblasts, primers against an amplicon in exon 3-4 and exon 5-6 of ATRIP were used, respectively. 553 554 Predesigned qPCR primer pairs were ordered from Integrated DNA technologies (https://eu.idtdna.com) 555 (primers are listed in Supplementary Table 5).

556 **DNA damage inducers and inhibitors**

557 Cells were irradiated with 254nm ultraviolet radiation (UV-C) in the absence of culture medium using

the UVP Crosslinker (Analytikjena) or with X-rays (220kV, 13mA, 0.15mm copper filter, 3Gy/min)

using the Small Animal Radiation Research Platform (SARRP) (Xstrahl) at indicated doses. The

560 following genotoxic inducers and chemical inhibitors were used: Mitomycin C (MMC; Sigma-Aldrich),

561 Hydroxyurea (HU; Sigma-Aldrich), ATR kinase inhibitor (ATRi) (20 nM; BAY-1895344, also known

- as Elimusertib), ATM kinase inhibitor (ATMi) (10 µM; KU-55933) and DNA-PK inhibitor (DNA-PKi)
- 563 $(2 \mu M; KU-57788, also known as NU7441)$. Inhibitors were added to the medium 1h prior to treatment
- 564 with genotoxic stressors.

565 Plasmids and cloning

Plasmid DNA constructs containing the wild type cDNA sequence for ATRIP, ATR, and RPA1 inserted
into a modified pcDNA3.1(+) expression vector encoding a N-terminal 3xFlag-tag, a C-terminal V5tag, or a C-terminal c-Myc-tag, respectively, were purchased from GenScript. Mutant ATRIP plasmid

569 constructs containing the cDNA sequence for wild type ATRIP lacking exon 5 inserted into a

570 pcDNA3.1(+) vector encoding a N-terminal 3xFlag-tag were generated by GenScript. All plasmids were 571 transformed in DH10B or DH5α Escherichia coli. DNA was isolated using NucleoBond Xtra Midi kit

- 572 (Macherey-Nagel). HEK293T cells were transiently co-transfected with ATR, RPA1, and either wild
- 573 type ATRIP or mutant ATRIP plasmid DNA. Transfections were performed with branched 25kDa
- 574 polethylenimine (PEI).

575 **Co-immunoprecipitation**

576 Wild type or mutant ATRIP protein was immunoprecipitated by incubating 250 μ g of whole cell lysate 577 with 4 μ g of anti-FLAG antibody (Sigma-Aldrich; F3165) or 4 μ g of isotype-matched IgG antibody

578 (Sigma-Aldrich; 12-371) overnight at 4°C, followed by incubation with Dynabeads Protein G

579 (Invitrogen) for 1h at 4°C. Beads with protein complexes were washed six times with IP High buffer

- 580 without extra salt and detergents (Nuclear complex Co-IP Kit; Active Motif; 54001). Precipitates were
- 581 eluted by boiling in Laemmli Sample buffer and analyzed by immunoblotting.

582 Immunoblotting

583 Cells were lysed in RIPA (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% 584 SDS, 50 mM Tris, pH 8.0) (Roche) complemented with protease inhibitors (cOmplete ULTRA; Roche) and phosphatase inhibitors (PhosSTOP; Roche). Soluble fraction was normalized prior to protein 585 586 separation by SDS-PAGE using a 4-15% Criterion TGX Stain-Free Protein Gel (Bio-Rad) and followed by semi-dry transfer to a nitrocellulose membrane (Bio-Rad). Membranes were blocked with 5% nonfat 587 588 dry milk (Cell Signaling Technology (CST)) in phosphate buffered saline with 0.1% Tween 20 (PBS-589 T) or 5% bovine serum albumin (BSA) (Roche) in PBS-T for 1h at room temperature, incubated with 590 primary antibodies overnight at 4°C or for 2h at RT, followed by incubation with secondary antibodies conjugated to horseradish peroxidase (HRP). Membranes were developed using enhanced 591 592 chemiluminescence reagents (SuperSignal West Dura or Femto; Thermo Fisher Scientific) on a 593 Chemidoc imaging system (Bio-Rad). All immunoblotting experiments were performed at least twice, 594 and representative data are shown. Protein levels were quantified using the Image Lab software (Bio-595 Rad). All uncropped images can be retrieved in the Source File. The following primary antibodies were probed: anti-Flag (1:1000; Sigma-Aldrich; F3165), anti-V5 (1:1000; Invitrogen; R960-25), anti-c-Myc 596 597 (1:2000; Abcam; ab9106), anti-ATRIP (1:1000; Cell Signaling Technology (CST); #97687), anti-TOPBP1 (1:2000; Bethyl Laboratories; A300-111A), anti-RPA70/RPA1 (1:2000; Abcam; ab176467), 598 599 anti-ATR (1:1000; CST; #2790), anti-CHK1 (1:1000; Santa Cruz; sc-8408), anti-phospho-ATR (T1989) 600 (1:1000; Invitrogen; PA5-77873), anti-phospho-CHK1 (S317) (1:1000; CST; #8191), anti-\beta-tubulin-HRP (1:5000; Abcam; ab21058) and anti-GAPDH-HRP (1:2000; CST; #8884). The secondary 601 antibodies goat anti-mouse IgG (H+L)-HRP (1:10000; Invitrogen; G-21040) and goat anti-rabbit IgG-602 603 HRP (1:2000; CST; #7074) were used. To confirm the specificity of the anti-phospho-ATR antibody, 604 the membrane was dephosphorylated using Lambda Protein Phosphatase (New England Biolabs; 605 P0753S). Briefly, the membrane was incubated with blocking buffer containing 400 U/ml Lambda Protein Phosphatase and 1 mM MnCl₂ overnight at 4°C prior to incubation with the primary antibody. 606

607 Immunofluorescence

608 Primary fibroblasts were grown on 22 mm glass coverslips (Menzel Gläser) 24h before starting the experiment. Cells were pulse-labeled with 10 µM EdU (Click-iT[™] Plus EdU Alexa Fluor[™] 647 609 610 Imaging Kit; Invitrogen; C10640) for 30 min and concomitantly treated with a DNA damage inducer. 611 For RPA staining, cells were treated with pre-extraction buffer (0.5% Triton X-100, 20 mM HEPES, pH 612 7.4, 100 mM NaCl, 3 mM MgCl2, and 300 mM sucrose in distilled water) prior to fixation. At the 613 indicated time post-treatment, cells were fixed with 3% paraformaldehyde (PFA) in PBS for 20 min, followed by simultaneous permeabilization and blocking in 1% BSA (Sigma-Aldrich) and 0.2% Triton 614 615 X-100 in PBS for 30 min. Primary antibody incubations were performed for 1h at RT with anti-yH2AX 616 S139 (1:500; BioLegend; 613402) and anti-RPA32/RPA2 (1:500; Merck; MABE285) or overnight at 4°C with anti-ATR (1:250; CST; #13934). After washing, coverslips were incubated with secondary 617 618 antibodies for 1h at RT (goat anti-rabbit Alexa Fluor 488 (1:1000; Invitrogen; A-11008) or goat anti-619 mouse Alexa Fluor 488 (1:1000; Invitrogen; A-11001)). EdU staining was performed by incubation with 620 Click-iT reaction cocktail according to the manufacturer's protocol. Coverslips were mounted in 621 Fluoromount (Sigma-Aldrich) containing DAPI nuclear stain. Images were acquired with a Leica DM6 622 B microscope (Leica Microsystems) using a HCX PL APO 40x/1.3 oil objective, equipped with Las X 623 software (Leica Microsystems). Identical microscope settings and image processing steps were used for all samples of the same experiment. Quantifications of DNA damage foci and analysis of signal 624 625 intensities was performed using Fiji software (version 2.9.0). Pooled data from three independent 626 experiments are shown. A minimum of 150 cells were analyzed per experimental condition.

627 Micronucleus assays

628 The G0 and MMC micronucleus assay. The G0 and MMC micronucleus (MN) assay were performed, as described previously by Beyls et al.⁸⁰ and Francies et al.⁸¹, respectively. Briefly, fresh whole blood 629 cultures were prepared by adding 0.5 ml blood to 4.5 ml RPMI. The culture medium was supplemented 630 with 10% FBS and 1% penicillin-streptomycin. The cultures were irradiated with 0.5 or 1 Gy (G0 MN 631 assay) or treated with 0.02 µg/ml MMC (MMC MN assay) and subsequently stimulated with 2% PHA-632 633 M. Cytochalasin B (6 µg/ml; Sigma-Aldrich) was added to block cytokinesis 23h post-stimulation. After 634 70h culture time, cells were harvested and exposed to a cold hypotonic shock with 0.075 M KCl and fixed in ice-cold methanol/acetic acid solution. Acridine orange (10 µg/ml; Sigma-Aldrich) stained 635 slides were scored according to the criteria described by Fenech et al.⁸² MN were scored manually on a 636 fluorescence microscope in 1000 binucleate (BN) cells per condition. 637

638 The S micronucleus assay. Fresh whole blood cultures were set-up as described above and cell 639 proliferation was immediately stimulated with 2% PHA-M. Following 96h of culture, the cells were 640 pulse labeled with 10 μ M EdU for 30 min, irradiated with 0.5 or 1 Gy, and cytochalasin B (6 μ g/ml; 641 Sigma-Aldrich) was added. After an additional 24h of culture, the cells were harvested and fixed 642 according to the G0 MN protocol described previously. Slides were prepared and the cells were 643 additionally fixed in 3% PFA for 20 min and permeabilized with ice-cold 0.2% Triton X-100 for 10 644 min. Subsequently, EdU staining was performed according to the manufacturer's protocol and the slides 645 were mounted in Fluoromount containing DAPI nuclear stain. MN were scored in 1000 EdU positive 646 BN cells per condition.

647 Flow cytometry

648 *Cell cycle analysis.* Fibroblasts were seeded at a density of 7,000 cells/cm² and cultured for 24h. The cells were exposed to a DNA damage inducer (0.02 µg/ml MMC, 200 J/m² UV-C, or 1 mM HU) and 649 650 subsequently cultured for the indicated time. The cells were pulse-labeled with 10 µM EdU for 30 min before harvesting. The cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining 651 Buffer Set (Thermo Fisher Scientific; 00-5523-00) following the manufacturer's protocol. EdU staining 652 653 was performed by incubating the cells with the Click-iT reaction cocktail, prepared as per 654 manufacturer's instructions. The cells were stained with permeabilization buffer containing antiyH2AX-AF488 (S139) (2F3; BioLegend; 613406) for 30 min on ice when indicated. DNA content was 655 stained using permeabilization buffer containing DAPI. Acquisition of the stained cells was performed 656 657 using a BD LSRFortessa or BD FACSymphony A3 (BD Biosciences). Subsequent data analysis was 658 performed with the FlowJo v10.10.0 software (BD Life Sciences).

659 EdU pulse-chase assay. The EdU pulse-chase assay was performed as previously described by Duthoo et al.⁶⁰, with minor adjustments. Briefly, PHA blasts were cultured for 96h in a 48-well plate (250,000 660 cells in 500 µl) in the presence of 2% PHA-M. Next, the cells were pulse-labeled with 10 µM EdU for 661 30 min and concurrently exposed to a DNA damage inducer (200 J/m² UV-C or 4 Gy IR). MMC (0.02 662 663 µg/ml) was added to the culture 24h prior to EdU labeling. Subsequent harvesting of the cells was performed at various time points, ranging from 0 to 15h, with intervals of 3h. The cells were fixed and 664 permeabilized using the Foxp3 / Transcription Factor Staining Buffer Set. Subsequent EdU staining was 665 performed using the Click-iT reaction cocktail and DNA was stained with permeabilization buffer 666 containing DAPI. Acquisition was performed using a BD LSRFortessa (BD Biosciences) and data was 667 analyzed with the FlowJo software. 668

669 *Proliferation assay.* Cryopreserved PBMCs were resuspended in PBS at a density of 1×10^6 cells per 670 ml. Cells were labeled with CellTrace Violet (CTV) (1 μ M; Thermo Fisher Scientific; C34557) and 671 incubated for 10 min at 37°C. Unbound CTV was quenched by washing the cells with PBS 672 supplemented with 1% FCS. The cells were seeded in a 48-well plate (250,000 cells in 500 μ l), treated

with 0.02 μg/ml MMC, and subsequently stimulated with 2% PHA-M. After 96h of culture, PHA blasts
were harvested and stained with anti-CD3-AF700 (SK7; BioLegend; 344822), anti-CD4-FITC (RPA-T4; BD Bioscience; 561005), anti-CD8-PE-Cy7 (RPA-T8; BD Bioscience; 557746), and FcR block
(BioLegend; 422302) in PBS. After 30 min of staining, cells were washed, stained with propidium iodide
(PI), and acquired using a BD LSRFortessa (BD Biosciences). Subsequent data analysis was performed
with the FlowJo software.

679 Immunophenotyping. Cryopreserved PBMCs were thawed in 37°C preheated complete medium (RPMI-680 1640 medium supplemented with GlutaMAX, 10% FCS, 1% penicillin-streptomycin (Pen/Strep) (10,000 U/mL; Gibco; 15140122), 1 mM sodium pyruvate (Gibco; 11360070), 1% non-essential amino 681 682 acids (NEAA) (Gibco; 11140035), and 50 µM 2-mercaptoethanol (Gibco; 31350010)). Cells were left to recuperate for 30 min at 37°C and 5% CO2 after removal of DMSO. Cells were counted and 683 2,000,000 cells were plated for each panel. Cells were first stained with FcR block (BioLegend; 422302) 684 685 together with biotin conjugated antibodies and Zombie UVTM Fixable Viability dye (BioLegend; 423107) in PBS. In a second step, a first set of surface markers were stained with a mixture of antibodies 686 687 in FACS buffer (DPBS pH7.4, 1% Bovine Serum Albumin, 0.05% NaN₃, 1 mM EDTA) and Brilliant 688 Stain buffer (BD Biosciences). After 30 min of staining, cells were washed and stained overnight with 689 a second set of antibodies. Cells were fixed, permeabilized, and intracellular stained with antibodies 690 using the Foxp3/Transcription Factor Staining Buffer Set according to the manufacturer's protocol. 691 Acquisition and analysis of labeled cell suspensions was performed with a FACSymphony flow 692 cytometer (BD biosciences) and subsequent analysis of data with the FlowJo software. Antibodies used 693 to define PBMC populations can be found in Supplementary Table 6.

694 Single-cell RNA, TCR, BCR, and CITE sequencing

After thawing, up to $2x10^6$ PBMCs of each individual were counted, isolated, and spun down. The cell 695 696 pellet was resuspended and incubated for 30 min on ice with staining mix in PBS containing 0.04% 697 BSA, CD19-PE-Cy7, eFluor506 Fixable Viability dye, Human TruStain FcX (BioLegend; 422302), and 698 TotalSeq-C hashing antibodies (1:500; BioLegend). Two patient samples were multiplexed per lane 699 using TotalSeq-C Cell Hashing Antibodies. Both total live PBMCs and B cells were sorted and loaded 700 on different lanes. Sorted single-cell suspensions were resuspended at an estimated final concentration 701 of 2,000 cells/µl and loaded on a Chromium GemCode Single Cell Instrument (10x Genomics) to 702 generate single-cell gel beads in emulsion. The scRNA/Feature Barcoding/TCR libraries were prepared using the GemCode Single Cell 5' Gel Bead and Library kit, version 1.1 (10x Genomics; 1000165), 703 704 according to the manufacturer's instructions. The cDNA content of prefragmentation and post-sample 705 index PCR samples was analyzed using the 2100 BioAnalyzer (Agilent). Sequencing libraries were loaded on an Illumina NovaSeq flow cell at Vlaams Instituut voor Biotechnologie (VIB) Nucleomics 706 707 core with sequencing settings according to the recommendations of 10x Genomics, pooled in a 75:20:5 708 ratio for the gene expression, TCR, and antibody-derived libraries, respectively.

709 LAM-HTGTS

To study CSR patterns in B cells from F1Pt and healthy controls, a modified version of the linear
 amplification-mediated high-throughput genome-wide translocation sequencing (LAM-HTGTS)
 method was used, as described in Takada et al.⁴⁹.

713 Cytotoxicity assay

- Fibroblasts were seeded into 24-well plates at a density of 6,000 cells/cm² 24h before starting the
- 715 experiment. Cells were exposed to a DNA damage inducer (0.2 μg/ml MMC, 20 J/m² UV-C or 10 Gy
- 716 IR) and incubated with SYTOX Green nucleic acid stain (1:100000; Invitrogen) to indicate dead cells

717 during cell culture. Brightfield and fluorescence images were captured for 5 days with an 8h interval

718 with the CELLCYTE X (Cytena). Cell confluency and the number of dead cells were quantified using

719 CELLCYTE X Analysis software.

720 CRISPR-Select^{TIME} in mono-allelic cell system

Generation of mono-allelic ATR^{+/-} and ATRIP^{+/-} cell lines. An iCas9-MCF10A-WT clonal cell line with 721 722 stably integrated TRE3G Edit-R Inducible Lentiviral Cas9 construct (Horizon; CAS11229) was gifted 723 by Roderick L. Beijersbergen, The Netherlands Cancer Institute. To generate ATR^{+/-} cells, iCas9-724 MCF10A-WT cells were transfected with dual gRNAs targeting intron 1 and intron 46 of the ATR gene. 725 ATRIP^{+/-} cells were generated by transfecting the iCas9-MCF10A-WT cells with dual gRNAs targeting 726 intron 1 and intron 8 of the ATRIP gene. Two CRISPR RNAs (crRNAs) for Streptococcus pyogenes 727 Cas9 were designed using the online software Crispor (http://crispor.tefor.net/crispor.py). Note, the 728 crRNAs should be located in the non-coding region to avoid disturbing adjacent genes. The knock-out 729 efficiency of the designed crRNAs was analyzed by the online tool ICE (https://ice.synthego.com/#/), 730 and subsequently, the crRNAs with a high knock-out efficiency were selected to establish the monoallelic cell line. The iCas9-MCF10A-WT cells were seeded with 60% confluency in a 6 cm culture dish. 731 732 To induce the expression of the cas9 protein, 1 µg/ml doxycycline was added to the medium. After 24h, 733 7.5 µl of each crRNA (2 nmol) was mixed with 15 µl of trans-activating crRNA (tracrRNA, 5 nmol) 734 and was incubated at room temperature for 10 min to form crRNA:tracrRNA duplexes. Cells were subsequently transfected by 4 ml of culture medium containing 30 µl crRNA:tracrRNA duplexes, 15 µl 735 736 lipofectamine RNAiMAX (Thermo Fisher Scientific; 13778), and 500 µl Opti-MEM (Thermo Fisher 737 Scientific; 31985062). After 2 days of culture, single cells were sorted into 96-well plates with 100 µl 738 fresh medium per well using a FACS Aria III instrument (BD Biosciences) and subsequently kept in 739 culture 2-3 weeks until clonal cell lines were formed. Genomic PCR was performed to evaluate the 740 mono-allelic cell line. Primers targetting WT, ATR, or ATRIP deletion alleles were designed through 741 Primer3 (https://primer3.ut.ee/). Primers annealing to sequences outside the depletion region were used to identify the knock-out alleles. Primers annealing to sequences inside the deleted regions were used to 742 743 detect the WT allele. The cell colonies containing DNA that is successfully amplified by both two types 744 of primers were mono-allelic cell lines. DNA extraction was performed using the Quick-DNATM 745 Miniprep Plus Kit (Zymo Research; D4069). PCR was performed using 100 ng genomic DNA and 1% 746 agarose gel electrophoreses. For further verification, the PCR products of target sites were purified using 747 the QIAquick Gel Extraction Kit (QIAGEN; 28706) and were sent to Eurofins for Sanger sequencing. 748 The designed crRNAs and PCR primers are listed in Supplementary Table 7.

In vitro CRISPR-Select^{TIME} assay. In a 6-well plate, 17,500 iCas9-MCF10A-ATR^{+/-} or ATRIP^{+/-} cells 749 750 were seeded in 2 ml culture medium per well. To induce the expression of Cas9 protein, 1 µg/ml doxycycline was added in each well 24h before cell transfection. After 24h, 7.5 µl of the designed 751 752 crRNA (2 nmol) was incubated for 10 min at room temperature with 7.5 µl of tracrRNA (5nmol). Next, a mixture of 15 µl crRNA:tracrRNA duplexes, 7.5 µl lipofectamine RNAiMAX, 250 µl Opti-MEM, and 753 754 2 µl mixture of designed variant (10 µM) and WT* single-stranded oligodeoxynucleotide (ssODN) 755 repair templates was dripped onto the iCas9-MCF10A cells in fresh medium. The DNA repair template for each variant was designed in the online software Benchling (https://benchling.com). The design of 756 757 the synonymous mutations referring to the codon usage information were posted on 758 https://www.kazusa.or.jp. After 2 days, 50% of the edited cells were collected and DNA extraction was performed using the Quick-DNATM Miniprep Plus Kit. The remaining edited cells were kept in culture 759 and passaged every 3 days. After an additional 10 days of culture, all cells were collected and lysed for 760 DNA extraction using the Quick-DNATM Miniprep Plus Kit. Using Benchling and Primer3, PCR primers 761 762 for the amplification of the edited target sites in each variant were designed. Two rounds of PCR were

performed to prepare the PCR products for subsequent amplicon NGS. Firstly, primer pairs were used

- to amplify the specific edited target sites, containing overhangs with binding sites for the primers of the
- second round. Secondly, specific barcodes were added to each sample, including overhangs with
- barcodes or adaptors for NGS. After purifying the PCR products using the QIAquick Gel Extraction Kit,
- NGS was performed to sequence the PCR products of the DNA samples collected on day 2 and day 12.
 The ratio of read numbers of the knock-in of a variant relative to the WT* on day 2 and day 12 were
- The ratio of read numbers of the knock-in of a variant relative to the WT* on day 2 and day 12 were compared to determine the functional characteristics of the different mutations. The designed crRNAs,
- PCR primers, and DNA repair templates are listed in Supplementary Table 8 and 9.

771 Statistical analyses

- 772 GraphPad Prism software (version 10) was used for all statistical analyses. As indicated in the figure
- 1773 legends, results were analyzed with a two-tailed Mann-Whitney test, multiple paired t-tests, or Kruskal-
- Wallis test combined with Dunn's multiple comparisons test. The threshold for statistical significance
- was set to p<0.05. Representative immunofluorescence images and flow cytometric plots are shown. R
 (v4.3.2) and RStudio (v2023.09.1+494) were used for analysis of scRNA, TCR, BCR, and CITE
- requencing data. The analytical pipeline consisted of Cellranger (v6.1.1) for quality control. CITE-seq
- and scRNA-seq data were analyzed using Seurat package (v5), with an embedded Presto package
- 779 (v1.0.0) for differential gene expression analysis. Analysis of TCR-seq and BCR-seq data was conducted
- vising the Diversity AnaLysis Interface (DALI, v2.0.0).

781 Supplementary Materials

- 782 Case descriptions
- 783 Supplementary figures 1-8
- 784 Supplementary tables 1-9
- 785

786 **References:**

- Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA
 Damage Response. *Mol Cell* 66, 801–817 (2017).
- Ciccia, A. & Elledge, S. J. The DNA Damage Response: Making It Safe to Play with Knives. *Mol Cell* 40, 179–204 (2010).
- 791 3. Cimprich, K. A. & Cortez, D. ATR: An essential regulator of genome integrity. *Nat Rev Mol Cell Biol* 9, 616–627 (2008).
- Matsuoka, S. *et al.* ATM and ATR Substrate Analysis Reveals Extensive Protein Networks
 Responsive to DNA Damage. *Science (1979)* **316**, 1160–1166 (2007).
- Jazayeri, A. *et al.* ATM- and cell cycle-dependent regulation of ATR in response to DNA doublestrand breaks. *Nat Cell Biol* 8, 37–45 (2006).
- Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: Ensuring faithful duplication of a challenging genome. *Nat Rev Mol Cell Biol* 18, 622–636 (2017).
- 799 7. Klein, A. De *et al.* Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. *Current Biology* **10**, 479–482 (2000).
- 8. Brown, E. J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. *Genes Dev* 14, 397–402 (2000).
- 803 9. Nam, E. A., Zhao, R. & Cortez, D. Analysis of mutations that dissociate G 2 and essential S phase
 804 functions of human Ataxia Telangiectasia-mutated and Rad3-related (ATR) protein kinase. *Journal*805 of *Biological Chemistry* 286, 37320–37327 (2011).
- 806 10. Lam, F. C. The DNA damage response from cell biology to human disease. *J Transl Genet Genom* 807 6, 204–222 (2022).
- 808 11. Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: Partners in Checkpoint Signaling.
 809 Science (1979) 294, 1713–1716 (2001).
- 810 12. O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation
 811 affecting expression of ataxia telangiectasia and Rad3 related protein (ATR) results in Seckel
 812 syndrome. *Nat Genet* 33, 497–501 (2003).
- 813 13. Goodship, J. *et al.* Autozygosity Mapping of a Seckel Syndrome Locus to Chromosome 3q22.1-q24.
 814 Am. J. Hum. Genet 67, 498–503 (2000).
- 815 14. Ogi, T. *et al.* Identification of the First ATRIP Deficient Patient and Novel Mutations in ATR
 816 Define a Clinical Spectrum for ATR ATRIP Seckel Syndrome. *PLoS Genet* 8, (2012).
- 817 15. Mokrani-Benhelli, H. *et al.* Primary Microcephaly, Impaired DNA Replication, and Genomic
 818 Instability Caused by Compound Heterozygous ATR Mutations. *Hum Mutat* 34, 374–384 (2013).
- 819 16. Llorens-Agost, M. *et al.* Analysis of novel missense ATR mutations reveals new splicing defects underlying Seckel syndrome. *Hum Mutat* **39**, 1847–1853 (2018).
- 821 17. Bass, T. E. *et al.* ETAA1 acts at stalled replication forks to maintain genome integrity. *Nat Cell Biol*822 18, 1185–1195 (2016).
- Wang, X. *et al.* 3.9 Å structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP. *Structural Biology* 358, 1206–1209 (2017).
- Beshpande, I. *et al.* Structural Basis of Mec1-Ddc2-RPA Assembly and Activation on SingleStranded DNA at Sites of Damage. *Mol Cell* 68, 431-445.e5 (2017).
- 827 20. Rao, Q. et al. Cryo-EM structure of human ATR-ATRIP complex. Cell Res 28, 143–156 (2018).
- Belacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K. I. & Karnitz, L. M. The Rad9-Hus1Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. *Genes Dev* 21, 1472–1477 (2007).
- Haahr, P. *et al.* Activation of the ATR kinase by the RPA-binding protein ETAA1. *Nat Cell Biol* 18, 1196–1207 (2016).

- 832 23. Cybulski, C. *et al.* Variants in ATRIP are associated with breast cancer susceptibility in the Polish
 833 population and UK Biobank. *Am J Hum Genet* **110**, 648–662 (2023).
- 834 24. Matos-Rodrigues, G. E. *et al.* ATRIP protects progenitor cells against DNA damage in vivo. *Cell Death Dis* 11, (2020).
- Klingseisen, A. & Jackson, A. P. Mechanisms and pathways of growth failure in primordial dwarfism.
 Genes Dev 25, 2011–2024 (2011).
- Reynolds, J. J. *et al.* Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism. *Nat Genet* 49, 537–549 (2017).
- 840 27. Harley, M. E. *et al.* TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism. *Nat Genet* 48, 36–43 (2015).
- 842 28. Khetarpal, P., Das, S., Panigrahi, I. & Munshi, A. Primordial dwarfism: overview of clinical and genetic aspects. *Molecular Genetics and Genomics* 291, 1–15 (2016).
- 844 29. Conde, C. D. *et al.* Polymerase δ deficiency causes syndromic immunodeficiency with replicative stress. *Journal of Clinical Investigation* **129**, 4194–4206 (2019).
- 846 30. Conte, M. I. *et al.* Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia. *JCI Insight* **7**, (2022).
- 848 31. Cottineau, J. *et al.* Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. *Journal of Clinical Investigation* **127**, 1991–2006 (2017).
- 850 32. Cui, Y. *et al.* Combined immunodeficiency caused by a loss-of-function mutation in DNA
 851 polymerase delta 1. *Journal of Allergy and Clinical Immunology* 145, 391-401.e8 (2020).
- 852 33. Frugoni, F. *et al.* A novel mutation in the POLE2 gene causing combined immunodeficiency. *Journal* 853 of Allergy and Clinical Immunology 137, 635-638.e1 (2016).
- 34. Gineau, L. *et al.* Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. *Journal of Clinical Investigation* 122, 821–832 (2012).
- 856 35. Hughes, C. R. *et al.* MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. *Journal of Clinical Investigation* 122, 814–820 (2012).
- 858 36. Nichols-Vinueza, D. X. *et al.* POLD1 Deficiency Reveals a Role for POLD1 in DNA Repair and T
 859 and B Cell Development. *J Clin Immunol* 41, 270–273 (2021).
- Schmid, J. P. *et al.* Polymerase ε1 mutation in a human syndrome with facial dysmorphism,
 immunodeficiency, livedo, and short stature ('FILS syndrome'). *Journal of Experimental Medicine*209, 2323–2330 (2012).
- 863 38. Niu, Y. *et al.* Multiparametric and accurate functional analysis of genetic sequence variants using
 864 CRISPR-Select. *Nat Genet* 54, 1983–1993 (2022).
- 865 39. Masih, S. *et al.* Deciphering the molecular landscape of microcephaly in 87 Indian families by exome sequencing. *Eur J Med Genet* 65, (2022).
- 40. Mordes, D. A., Glick, G. G., Zhao, R. & Cortez, D. TopBP1 activates ATR through ATRIP and a
 PIKK regulatory domain. *Genes Dev* 22, 1478–1489 (2008).
- 869 41. Ball, H. L., Myers, J. S. & Cortez, D. ATRIP Binding to Replication Protein A-Single-stranded DNA
 870 Promotes ATR-ATRIP Localization but Is Dispensable for Chk1 Phosphorylation. *Mol Biol Cell* 16, 2372–2381 (2005).
- 42. Namiki, Y. & Zou, L. ATRIP associates with replication protein A-coated ssDNA through multiple
 interactions. *Proc Natl Acad Sci U S A* 103, 580–585 (2006).
- 43. Itakura, E. *et al.* Amino-terminal domain of ATRIP contributes to intranuclear relocation of the ATRATRIP complex following DNA damage. *FEBS Lett* 577, 289–293 (2004).
- 44. Lee, Y. N. *et al.* Characterization of T and B cell repertoire diversity in patients with RAG deficiency.
 Sci Immunol 1, (2016).

- Foth, S., Völkel, S., Bauersachs, D., Zemlin, M. & Skevaki, C. T Cell Repertoire During Ontogeny
 and Characteristics in Inflammatory Disorders in Adults and Childhood. *Front Immunol* 11, (2021).
- 46. Pan-Hammarström, Q. *et al.* Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. *Journal of Experimental Medicine* 203, 99–110 (2006).
- Sun, X. *et al.* ATR kinase activity promotes antibody class switch recombination in B cells through cell cycle regulation without suppressing DSB resection and microhomology usage. *J Leukoc Biol* 110, 1101–1112 (2021).
- 48. Hu, J. *et al.* Detecting DNA double-stranded breaks in mammalian genomes by linear amplificationmediated high-throughput genome-wide translocation sequencing. *Nat Protoc* 11, 853–871 (2016).
- 49. Takada, S. *et al.* Causative mechanisms and clinical impact of immunoglobulin deficiencies in ataxia telangiectasia. *Journal of Allergy and Clinical Immunology* 153, 1392–1405 (2024).
- Saha, J., Wang, S. & Davis, A. J. Examining DNA double-strand break repair in a cell cycle dependent manner. *Methods Enzymol* 591, 97–118 (2017).
- 891 51. Liu, S. *et al.* ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation. *Mol Cell*892 43, 192–202 (2011).
- Nam, E. A. *et al.* Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- mutated and
 Rad3-related (ATR) kinase. *Journal of Biological Chemistry* 286, 28707–28714 (2011).
- 53. Lossaint, G. *et al.* Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest. *J Cell Sci* 135, (2022).
- Stiff, T. *et al.* ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. *EMBO Journal* 25, 5775–5782 (2006).
- 899 55. Hanasoge, S. & Ljungman, M. H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase. *Carcinogenesis* 28, 2298–2304 (2007).
- 56. Toledo, L. I. *et al.* XATR prohibits replication catastrophe by preventing global exhaustion of RPA.
 Cell 155, 1088–1103 (2013).
- 90357.Eklund, H., Uhlin, U., Arneg(Ardh, M. F., Logan, D. T. & Ar Nordlund, P. Structure and function904of the radical enzyme ribonucleotide reductase. *Prog Biophys Mol Biol* 77, 177–268 (2001).
- 58. Cliby, W. A. *et al.* Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. *EMBO J* 17, 159–169 (1998).
- 90759.Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G 2 /M DNA908damage checkpoint. Genes Dev 14, 1448–1459 (2000).
- 909 60. Duthoo, E., Vral, A. & Baeyens, A. An updated view into the cell cycle kinetics of human T
 910 lymphocytes and the impact of irradiation. *Sci Rep* 12, 1–12 (2022).
- 911 61. Murga, M. *et al.* A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. *Nat Genet* 41, 891–898 (2009).
- 913 62. Jeon, Y. *et al.* TopBP1 deficiency causes an early embryonic lethality and induces cellular senescence
 914 in primary cells. *Journal of Biological Chemistry* 286, 5414–5422 (2011).
- 81. Shou, Z. W. *et al.* An Essential Function for the ATR-Activation-Domain (AAD) of TopBP1 in
 81. Mouse Development and Cellular Senescence. *PLoS Genet* 9, (2013).
- 91764.Shin, U. *et al.* Large-scale generation and phenotypic characterization of zebrafish CRISPR mutants918of DNA repair genes. DNA Repair (Amst) 107, (2021).
- 65. Zou, L. & Elledge, S. J. Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes. *Science (1979)* 300, 1538–1542 (2003).
- Murga, M. *et al.* A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. *Nat Genet* 41, 891–898 (2009).
- Ruzankina, Y. *et al.* Deletion of the Developmentally Essential Gene ATR in Adult Mice Leads to
 Age-Related Phenotypes and Stem Cell Loss. *Cell Stem Cell* 1, 113–126 (2007).

- 925 68. Schuler, F. *et al.* Checkpoint kinase 1 is essential for normal B cell development and
 926 lymphomagenesis. *Nat Commun* 8, (2017).
- 927 69. Schoeler, K. *et al.* CHK1 dosage in germinal center B cells controls humoral immunity. *Cell Death* 928 *Differ* 26, 2551–2567 (2019).
- 929 70. Menolfi, D. *et al.* Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR
 930 and RPA. *Nat Commun* 9, 1–16 (2018).
- 931 71. Willemsen, M. *et al.* DNA replication–associated inborn errors of immunity. *Journal of Allergy and Clinical Immunology* 151, 345–360 (2023).
- 933 72. Guo, C. *et al.* XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency. *Journal of Allergy and Clinical Immunology* **136**, 1007–1017 (2015).
- 935 73. Butler, M. G., Hall, B. D., Maclean, R. N. & Lozzio, C. B. Do some patients with Seckel syndrome have hematological problems and/or chromosome breakage? *Am J Med Genet* 27, 645–649 (1987).
- 937 74. Woods, C. G., Leversha, M. & Rogers, J. G. Severe intrauterine growth retardation with increased
 938 mitomycin C sensitivity: A further chromosome breakage syndrome. *J Med Genet* 32, 301–305
 939 (1995).
- Arnold, S. R., Spicer, D., Kouseff, B., Lacson, A. & Gilbert-Barness, E. Seckel-like syndrome in three siblings. *Pediatric and Developmental Pathology* 2, 180–187 (1999).
- 942 76. Hayani, A., Suarez, C. R., Molnar, Z., LeBeau, M. & Godwin, J. Acute myeloid leukaemia in a patient with Seckel syndrome. *J Med Genet* 31, 148–149 (1994).
- 944 77. Majewski, F. & Goecke, T. Studies of microcephalic primordial dwarfism I: Approach to a delineation of the Seckel syndrome. *Am J Med Genet* 12, 7–21 (1982).
- 94678.Thompson, E. & Pembrey, M. Seckel syndrome: An overdiagnosed syndrome. J Med Genet 22, 192–
201 (1985).
- 948 79. Nykamp, K. *et al.* Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genet Med* 19, 1105–1117 (2017).
- 80. Beyls, E., Baeyens, A. & Vral, A. The cytokinesis-block micronucleus assay for cryopreserved whole
 blood. *Int J Radiat Biol* 97, 1252–1260 (2021).
- 81. Francies, F. Z. *et al.* Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. *DNA Repair (Amst)* 61, 17–24 (2018).
- 954 82. Fenech, M. Cytokinesis-block micronucleus cytome assay. *Nat Protoc* 2, 1084–1104 (2007).

955

956

957 Statements

Personally identifiable patient information was redacted in accordance with medRxiv requirements. IDs
used in this study were not known to anyone outside the research group, unless they were previously
published and are thus part of the public domain (PMID23144622 and PMID35568357).

961 Acknowledgments

962 We gratefully thank the patients and family for consenting to this research. The valuable input from 963 prof. Penny Jeggo, prof. Grant Stewart, prof. Mark O'Driscoll, Dr. Angela Brady, Dr. Mohnish Suri, 964 Dr. Pradeep Vasudevan, Dr. Emma Hobson, Dr. Kaljit Bhuller, and Dr. Mandal Kausik on the clinical 965 phenotype of the ATRIP and ATR patients is warmly appreciated. We thank Karlien Claes for the patient centered support, Sylvie De Buck for the administrative assistance, Lieselotte Vande Walle and Sarah 966 Ghistelinck for the experimental expertise, and Julie Smet for providing NK cytotoxicity data. We 967 968 acknowledge the VIB Flow Core and VIB Single Cell Core of the VIB center for inflammation research 969 for their assistance and expertise in experimental design.

970 Funding

971 This work is supported (not financially) by the European Reference Network for Rare

Immunodeficiency, Autoinflammatory, and Autoimmune Diseases Network (ERN-RITA). This work
 was funded by Research Foundation Flanders (FWO) (FWOTBM2018000102) and VIB Grand

974 Challenge. Simon Tavernier is a beneficiary of a senior postdoctoral FWO grant (1236923N). Sebastian

975 Riemann is funded by Ghent University (BOF23/DOC/013). Centre for Primary Immune deficiency

- 976 Ghent (CPIG) is recognized as Jeffrey Modell Diagnostic and Research center and funded by JMF
- 977 foundation.

978 Author contributions

- 979 Conceptualization: ED, EB, LB, TG, AB, AV, CSS, QPH, FH, KBMC, SJT
- 980 Methodology: ED, EB, LB, TG, AB, AV, CSS, QPH, FH, KBMC, SJT
- 981 Investigation: ED, EB, LB, PH, LJ, SR, BP, LD, VDB, MDB, JS, SJT
- 982 Clinical data collection: LH, TK, GM, FH
- 983 Visualization: ED, EB, LB, SJT
- 984 Funding acquisition: SR, EVB, AV, AB, FH, KBMC, SJT
- 985 Project administration: ED, EB, LB, SJT
- 986 Supervision: FH, KBMC, SJT
- 987 Writing original draft: LB, ED, EB, SJT
- 988 Writing review & editing: All authors

989 Competing interests

990 The authors declare that they have no competing interests.

991 Data availability

- 992 Code for scRNA-seq data analysis will be made available on GitHub upon publication. The plasmids
- will be made available via GeneCorner upon publication (<u>https://bccm.belspo.be/genecorner</u>). The
- ATRIP variant will be submitted to ClinVar and the Leiden Open Variation Database (LOVD) upon
- 995 publication.

996 Materials & Correspondence

997 Correspondence and requests for materials should be addressed to Filomeen Haerynck and Kathleen998 Claes.

999 Figures and Tables



1000

1001 Figure 1. Identification of homozygous complete loss-of-function *ATRIP* variants in patients with MPD.

1002 a Family pedigree with allele segregation of ATRIP splice variant. Index patient (F1Pt) is marked with an arrow 1003 and clinical phenotype and genotype is indicated in the legend. A detailed phenotypical description can be found 1004 in Supplementary Materials. b Fragment analysis and size profiles of PCR-amplified cDNA extracted from PHA 1005 blasts for F1Pt, parents (F1Fa and F1Mo), and a healthy control (HC). Arrows indicate the position of forward and 1006 reverse primers used for PCR amplification. Percentages represent relative quantification of the 538bp wild type 1007 and 380bp mutant (r.671_829del) fragment. Data is representative of five independent experiments. c 1008 Electropherograms of cDNA extracted from PHA blasts of F1Pt and a control. Nucleotide numbering is in 1009 accordance with ENST00000320211.1. Depicted profiles are reflective of five independent experiments. d 1010 Schematic illustration of biallelic ATRIP variant effect at both transcript and amino acid level. e Endogenous 1011 protein expression of ATRIP and complex partners in primary fibroblasts from F1Pt, father (F1Fa), and controls 1012 (HCs). B-tubulin was used as loading control. Western blot image is reflective of four independent experiments. f 1013 Peak size profile in base pairs (bp) of PCR-amplified cDNA extracted from EBV immortalized lymphoblastoid

- 1014 cell lines (EBV-LCLs) generated from the father (F1Fa) treated with and without puromycin. Percentages represent
- 1015 relative ratio of wild type (835bp) and mutant (380bp) fragments. Data is reflective of two independent
- 1016 experiments. **g** Schematic overview of the effect of the biallelic *ATRIP* variant at the protein level and an overview
- 1017 of the ATR-ATRIP complex with downstream effector CHK1. **h** HEK293T cells were transiently co-transfected
- 1018 with 3xFLAG-tagged ATRIP (3xFLAG-wtATRIP or 3xFLAG-mutATRIP), RPA70-Myc, and ATR-V5. After
- immunoprecipitation with anti-FLAG or control IgG, interaction between ATRIP (FLAG) and ATR (V5), RPA70
 (Myc), and endogenous TOPBP1 was examined by western blot analysis. B-tubulin serves as a loading control.
- 1021 Results are reflective of three independent experiments. Source data are provided as a Source Data file.



1022

Figure 2. Loss of ATRIP is associated with an immune deficiency, characterized by CD4⁺ T cell lymphopenia
 and reduced B and CD16⁺ NK lymphocytes.

1025 a Total numbers (No) of CD4⁺ T, CD8⁺ T, NK, and B cells in the peripheral blood from the ATRIP patient (F1Pt) 1026 over time. Shading indicates the age-based reference range. b Flow cytometric (FCM) immunophenotyping of 1027 F1Pt, family members, and age-matched healthy controls (HCs). Percentages of CD4⁺ T, CD8⁺ T, NK, and B cells 1028 in PBMCs from F1Pt, sister (F1Si), mother (F1Mo), and father (F1Fa). Data represents one experiment, with each 1029 datapoint representing one biological replicate. Mean and SEM are shown. c IgG2 concentration (Conc.) in the 1030 peripheral blood from F1Pt over time. Shading indicates the age-based reference range. Immunoglobulin 1031 substation therapy is indicated. d Total numbers (No) of neutrophils in the peripheral blood from F1Pt, 1032 demonstrating intermittent neutropenia. Shading indicates the age-based reference range. e Hemoglobulin 1033 concentration (Conc.) in the peripheral blood from F1Pt over time. Shading indicates age-based reference range. 1034 Corticosteroid (CORT) and anti-CD20 mAb treatment (aCD20) is indicated. f UMAP plot depicting cluster 1035 annotation of 25 unique T and NK subsets (left). Analysis was performed using concatenated 25-parameter FCM 1036 data of PBMCs obtained from HCs (n = 6) and F1Pt. Contour plots of HCs (middle, top) and F1Pt (middle, bottom). 1037 Bar graph showing the relative proportion of HCs and F1Pt within each T and NK subset cluster (right). g UMAP 1038 plot demonstrating cluster annotation of 18 unique B and innate subsets (left). Analysis was performed using 1039 concatenated 25-parameter FCM data of PBMCs obtained from HCs (n = 6) and F1Pt. Contour plots of HCs 1040 (middle, top) and F1Pt (middle, bottom). Bar graph depicting the relative contribution of HCs and F1Pt within 1041 each B and innate subset cluster (right). Data is representative of one experiment (f-i). Source data are provided as 1042 a Source Data file.



1043

1044Figure 3. TCR oligoclonality in CD8+ T_{EM} cells and altered class switch recombination (CSR) in absence of1045ATRIP.

1046 a CITE-seq profiling of PBMCs from healthy controls (HCs) (n =3) and ATRIP patient (F1Pt), identifying 25 1047 immune subsets. UMAP visualization of pooled CITE-seq data of HCs and F1Pt, displaying the identified subsets 1048 (left). UMAP plot of HCs (middle, top) and F1Pt (middle, bottom). Ratio of the 25 subsets in HCs and F1Pt, ranked 1049 based on the prevalence in F1Pt (right). b Circos plots showing the TRBV and TRAV pairing pattern of CD8⁺ T 1050 effector memory (T_{EM}) cells of healthy controls (HCs) and ATRIP patient (F1Pt). c Frequency of unique CD8⁺ 1051 T_{EM} cell clones in HCs and F1Pt. d Distribution of the CDR3 region lengths of TCR-α and TCR-β clones from 1052 HCs and F1Pt CD8⁺ T_{EM} cells. **e** Frequency of class switch recombination junctions per S region in HCs (n = 3) 1053 (junctions; n = 8305) and F1Pt (junctions; n = 2758). Mean and SD are shown. **f** Proportion of non-productive 1054 junctions (inversional recombination) per S region in HCs (n = 3) (junctions; n = 652) and F1Pt (junctions; n = 652)

- 1055 225). Mean and SD are shown. **g** Pie charts demonstrating the microhomology usage at Sμ-Sα junctions in HCs (n
- 1056 = 3) and F1Pt. Data represents one experiment (a-f). Source data are provided as a Source Data file.



1057

Figure 4. ATRIP deficiency presents with a DNA repair signature, interferon-driven immune dysregulation, and impaired T cell proliferation.

1060 a Heatmap representing the top 10 enriched hallmark gene sets (MSigDB) in PBMCs of F1Pt compared to HCs 1061 (n = 3). **b** Volcano plot showing the differentially expressed genes in PBMCs of F1Pt compared to HCs (n = 3). **c** 1062 Heatmap displaying the serum concentration of the cytokines IL-10, IL-21, IL-18, IP-10, IL-6, IL-17A, IL-31, 1063 IFNγ, IL-27, MIP31, ICAM-1, IL-1RA, Eotaxin-3, IL-22, and IL-1β in HCs (n = 13) and F1Pt pre- and post-1064 treatment with anti-CD20 mAb. d CD169 and CD64 expression on CD14⁺ monocytes of HCs (n = 6) and F1Pt pre- and post-treatment with anti-CD20 mAb (aCD20). Histograms of a representative HC and F1Pt are shown. 1065 1066 Bar plots depict median fluorescence (MFI). Mean and SEM are shown. e Lymphocyte transformation test (LTT) 1067 demonstrating the proliferative reponse of F1Pt whole blood to various stimuli. Data shows at least two 1068 independent analyses. **f** Proliferation analysis of CD8⁺ and CD4⁺ PHA blasts from HCs (n = 9) and F1Pt. PBMCs 1069 were labeled with CellTrace Violet (CTV) and stimulated with PHA for 96h. Precursor frequency (PF) and 1070 proliferation index (PI) of three independent experiments are depicted, with each datapoint representing one 1071 biological replicate. Mean and SD are shown. ns: not significant, *p<0.05, ***p<0.001, **** p<0.0001 (multiple 1072 unpaired t-tests). Source data are provided as a Source Data file.



1073

Figure 5. Absence of ATRIP does not abolish recruitment of ATR and its ability to phosphorylate substrates but reveals an insufficient ATR signaling response.

1076 a Fibroblasts from a healthy control (HC), ATRIP patient (F1Pt) and ATR patient (F02-98) were left untreated or 1077 exposed to 0.02 µg/ml Mitomycin C (MMC), 200 J/m² UV or 2 Gy IR. ATR was stained by immunofluorescence 1078 after 24h (MMC) or 3h (UV and IR) after exposure and ATR nuclear foci were quantified. Dot plot represents 1079 pooled data from three independent experiments; at least 150 cells were analyzed for each condition. The median 1080 number of foci is depicted. ns: not significant, **p<0.01, ***p<0.001, ****p<0.0001 (Kruskall-Wallis test and 1081 Dunn's multiple comparisons test). b Protein expression of phosphorylation events (T1989-pATR, S317-pCHK1) 1082 and total protein (ATR, CHK1) 3h post 200 J/m² UV radiation. Immunoblotting was performed on fibroblasts 1083 from F1Pt, F02-98, and HCs (n = 3). Western blot is representative of three independent experiments. GAPDH 1084 serves as a loading control. c pATR and pCHK1 levels shown in 2B were quantified. Bar graph depicts pATR and 1085 pCHK1 levels post UV treatment, expressed as a fold increase over the levels observed in the Mock condition. 1086 Mean and SD are shown. d Quantification of yH2AX nuclear fluorescence in HC and F1Pt fibroblasts 3h after 200 1087 J/m² UV exposure and concomitant EdU pulse-labeling. The mean yH2AX intensity per nucleus is shown for 1088 EdU- and EdU+ fibroblasts. Dot plot represents pooled data from three independent experiments. At least 200 1089 (EdU-) or 90 (EdU+) cells were analyzed per condition. The median value is depicted. ns: not significant, 1090 ****p<0.0001 (multiple Mann-Whitney tests and Bonferroni-Dunn multiple comparisons test). Representative 1091 immunofluorescence images with DAPI, EdU, and vH2AX staining is shown (left). White arrows indicate EdU-1092 cells. Scale bars are 20 µm. e yH2AX expression was determined by flow cytometric analysis 3h following 200 1093 J/m² UV exposure in EdU- (G0/G1 and G2/M phase) fibroblasts of HC and F1Pt. Median fluorescence intensity 1094 (MFI) of yH2AX (AF488) is annotated on the histogram. Data are reflective of one experiment. Source data are 1095 provided as a Source Data file.



1096

1097Figure 6. Loss of ATRIP results in compromised DNA replication and impaired cell cycle progression1098following replication stress.

a Schematic outlining the treatment protocol of the flow cytometric (FCM) assay used in **b** and **c**. **b** Cell cycle distributions of untreated fibroblasts from a healthy control (HC) and ATRIP patient (F1Pt). Representative FCM

1101 plots are shown (left). Scatter dot plot depicts data from eight independent experiments (right). Mean and SD are 1102 shown. ns: not significant (multiple paired t-tests). c FCM EdU pulse-labeling profiles of Mitomycin C (MMC) 1103 treated HC and F1Pt fibroblasts (top). Cells were exposed to 0.02 µg/ml MMC for 24h in the absence or presence 1104 of an ATR kinase inhibitor (ATRi, 20 nM). Histograms of EdU and DAPI intensity in S phase cells are shown 1105 (bottom). The median fluorescence intensity (MFI) is annotated on the histogram. Data is representative of three 1106 independent experiments. d Quantification of RPA nuclear fluorescence in HC and F1Pt fibroblasts 3h after 1 mM 1107 Hydroxyurea (HU) exposure and concomitant EdU pulse-labeling. The mean RPA intensity per nucleus is shown 1108 for EdU+ cells. Dot plot represents data from pooled data from three experiments. The median value is depicted. 1109 ns: not significant; ***p<0.001 (multiple Mann-Whitney tests and Bonferroni-Dunn multiple comparisons test). e 1110 FCM EdU pulse-labeling profiles of HC and F1Pt fibroblasts after the release from HU treatment (left). Cells were 1111 exposed to 1 mM HU for 3h, released for 3h, and subsequently harvested. Histograms of EdU intensity in S phase 1112 cells are shown (right). Data are representative of two experiments. f Cell cycle profiles of HC and F1Pt fibroblasts 1113 following 72h of 0.02 µg/ml MMC treatment, with and without 20 nM ATRi. The percentage of cells in G2/M 1114 phase is indicated. Data is representative of three independent experiments. g EdU pulse-chase kinetics of HC and 1115 F1Pt PHA blasts. Cells were untreated or treated with genotoxic inducers (0.02 µg/ml MMC or 200 J/m² UV), 1116 pulse-labeled with EdU, and harvested at indicated time points. Kinetic plots show percentages of EdU+ cells 1117 present in S phase (middle) and is representative of three independent experiments. h CellTrace Violet (CTV) 1118 profiles of CD8⁺ and CD4⁺ PHA blasts from HC and F1Pt after 96h of culture in the presence or absence of 0.02 1119 µg/ml MMC. Data is representative of two experiment. Source data are provided as a Source Data file.





1120

1123 a Immunofluorescence analysis of yH2AX foci in untreated EdU- fibroblasts from a healthy control (HC), ATRIP 1124 patient (F1Pt), and ATR patient (F02-98). yH2AX nuclear foci were quantified and are shown in a dot plot 1125 representing pooled data from three independent experiments. At least 150 cells were analyzed for each condition. 1126 The median number of foci is depicted. ****p<0.0001 (Kruskall-Wallis test and Dunn's multiple comparisons 1127 test). b Schematic of principle and treatment protocols of the micronucleus (MN) assays depicted in c and d. 1128 Cytokinesis is blocked with cytochalasin B (CytoB), allowing scoring of MN in binucleate (BN) cells. c, d Using 1129 the G0 and S MN assay, micronuclei were scored in untreated PHA blasts (c) and in PHA blasts exposed to 1 Gy 1130 of ionizing radiation (IR) (d). The Mitomycin C (MMC) MN assay was used to quantify micronuclei in PHA blasts 1131 treated with 0.02 µg/ml MMC (d). Mean MN values of a HC group are indicated by dashed lines. Dotted lines 1132 correspond to the mean+3SD and serve as a cut-off for sensitivity. Data of two independent experiments is shown 1133 for F1Pt, in each experiment an internal control (IC) was included. One experiment is performed for the family 1134 members (F1Si, F1Fa, F1Mo). e Bar graph depicts the total percentage of cell death after 120h of culture for 1135 untreated fibroblasts of HC, F1Pt, and F02-98. Mean and SD of at least three independent experiments is shown. f Schematic outlining of the treatment protocol of the cytotoxicity assay used in g and h. g, h Fibroblasts from HC, 1136 1137 F1Pt, and F02-98 were untreated or exposed to genotoxic inducers (0.2 µg/ml MMC, 20 J/m² UV, or 10 Gy IR)

1138 without (g) and with (h) kinase inhibitors (20 nM ATRi or 10 µM ATMi) as indicated. Cell death was monitored

1139 by live imaging up to 120h by quantifying the number of cells stained with SYTOX Green. Cell death kinetics are

1140 reflective of at least two independent experiments. i Bar graph indicating % cell death after 120h of treatment for

1141 the experiments shown in g and h. Source data are provided as a Source Data file.



1142

1143Figure 8. Quantitative functional assay identifies fitness defect in genome engineered ATRIP c.829+5G>T1144and ATRIP c.829+2T>G cells.

a Schematic representation of CRISPR-Select^{TIME} process for cell fitness testing. The depletion region of the ATR 1145 1146 and ATRIP genes are indicated. The CRISPR-Select cassettes for all the variants were transfected on day 2. Yellow 1147 cross indicates the various editing outcomes on target gene. The cell samples from day 2 (D2) and day 12 (D12) 1148 were collected and lysed for DNA extraction. PCR amplified the target edited sites of each sample and products 1149 were analyzed by NGS sequencing. b Schematic illustration of the modeled compound heterozygous (hez) and 1150 homozygous (hoz) ATRIP variants at the transcript level. c Cell fitness of MCF10A mono-allelic cells with the 1151 ATR and ATRIP variants. Each symbol within the bar represents an independent experiment. Each variant has three 1152 independent biological replicates. Mean and SEM are shown. Data of D12 is normalized to D2. **p<0.01, 1153 ***p<0.0001, ns: non-significant (two-tailed paired t-tests). Source data are provided as a Source Data file.

1154Table 1. Full blood count and basic immunology screening of ATRIP patients (F1Pt and CV1720). In case of F1Pt, the timepoints represent data prior to immunoglobulin1155treatment (age 0-5y), pre anti-CD20 mAb treatment (age 16-20y), and post anti-CD20 mAb treatment (age 16-20y#). Blue and red bold text signify reduced and elevated values,

1156 respectively, in comparison to age-matched reference values enclosed within brackets.

	F1Pt			CV1720			
Immunological features	0-5y	16-20y	16-20y#	6-10y	11-15y	11-15y	11-15y
Peripheral blood count							
White blood cell counts (/µl)	10830 (6000-15000)	1850 (4300-9640)	3060 (4300-9640)	5100 (5000-15500)	3200 (4500-13000)	3500 (4500-13000)	4500 (4500-13000)
Platelets (×10 ³ /mL)	311 (229-533)	87 (175-343)	194 (175-343)	279 (140-400)	218 (140-400)	199 (140-400)	190 (140-400)
Hemoglobin (g/dL)	12.1 (11.7-15.1)	7.4 (11.7-15.1)	13.4 (11.7-15.1)	13.9 (11.5-14.5)	14.0 (13.0-18.0)	16.0 (13.0-18.0)	15.0 (13.0-18.0)
Lymphocytes (/mL)	1191 (4000-10000)	1308 (1230-3420)	1050 (1230-3420)	1870 (1500-6500)	1430 (1500-6000)	1190 (1500-6000)	1830 (1500-6000)
Neutrophils (/mL)	7256 (1500-7500)	250 (1930-5780)	1280 (1930-5780)	2760 (1500-8000)	1410 (1800-8000)	1820 (1800-8000)	2090 (1800-8000)
Monocytes (/mL)	866 (400-1200)	117 (260-780)	410 (260-780)	350 (200-800)	230 (200-800)	420 (200-800)	330 (200-800)
Eosinophils (/mL)	106 (200-600)	161 (30-370)	260 (30-370)	100 (40-400)	70 (40-400)	70 (40-400)	180 (40-400)
Basophils (/mL)	217 (10-100)	0 (20-80)	40 (20-80)	40 (20-100)	30 (20-100)	0 (20-100)	20 (20-100)
Lymphocyte subsets							
T cells (CD3 ⁺) (/ μ L)	834 (900-4500)	1070 (700-2100)	1090 (700-2100)	N/A	N/A	N/A	1060 (1000-2200)
Helper T cells (CD4 ⁺) (/µL)	262 (500-2400)	551 (300-1400)	413 (300-1400)	N/A	N/A	N/A	710 (530-1300)
Cytotoxic T cells (CD8 ⁺) (/µL)	524 (300-1600)	492 (200-1200)	639 (200-1200)	N/A	N/A	N/A	277 (330-920)
B cells (CD19 ⁺) (/ μ L)	155 (200-2100)	139 (100-500)	16 (100-500)	N/A	N/A	N/A	480 (110-570)
NK cells (CD56 ⁺ /CD16 ⁺) (/ μ L)	N/A	58.9 (90-600)	53.5 (90-600)	N/A	N/A	N/A	150 (70-480)
Immunoglobulin levels							
IgM (g/L)	2.2 (0.27-0.63)	1.51 (0.4-2.48)	0.31 (0.4-2.48)#	N/A	N/A	N/A	N/A
IgA (g/L)	1.4 (0.5-1.24)	1.43 (0.71-3.65)	0.46 (0.71-3.65)#	N/A	N/A	N/A	N/A
Total IgG (g/L)	21.4 (4.7-9.3)	15.0 (7.0-16.0)	11.3 (7.0-16.0)	N/A	N/A	N/A	N/A
IgG2 (g/L)	0.28 (0.72-3.4)	1.79 (1.06-6.1)*	2.47 (1.5-6.4)*	N/A	N/A	N/A	N/A

1157 # after anti-CD20 mAb treatment, * under immunoglobulin replacement therapy.